

SUPPLEMENTAL MATERIAL

A multi-ethnic meta-analysis of genome-wide association studies in over 100,000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease

Maria Sabater-Lleal, PhD*; Jie Huang, MD, MPH*; Daniel Chasman, PhD*; Silvia Naitza, PhD*; Abbas Dehghan, MD, PhD*; Andrew D Johnson, PhD; Alexander Teumer, PhD; Alex P Reiner, MD, MSc; Lasse Folkersen, PhD; Saonli Basu, PhD; Alicja R Rudnicka, PhD; Stella Trompet, PhD; Anders Mälarstig, PhD; Jens Baumert, PhD; Joshua C. Bis, PhD; Xiuqing Guo, PhD; Jouke J Hottenga, PhD; So-Youn Shin, PhD; Lorna M Lopez, PhD; Jari Lahti, PhD; Toshiko Tanaka, PhD; Lisa R Yanek, MPH; Tiphaine Oudot-Mellakh, PhD; James F Wilson, PhD; Pau Navarro, PhD; Jennifer E Huffman, MSc; Tatijana Zemunik, MD, PhD; Susan Redline, MD MPH; Reena Mehra, MD, MSc; Drazen Pulanic, MD, PhD; Igor Rudan, MD, DSc; Alan F Wright, MBChB, PhD; Ivana Kolcic, MD; Ozren Polasek, MD, PhD; Sarah H Wild, MD, PhD; Harry Campbell, MD; J David Curb, MD, MPH; Robert Wallace, MD, MSc; Simin Liu, MD, DSc, MPH; Charles B. Eaton, MD, MSc; Diane M. Becker, ScD, MPH; Lewis C. Becker, MD; Stefania Bandinelli, MD; Katri Räikkönen, PhD; Elisabeth Widen, MD, PhD; Aarno Palotie, MD, PhD; Myriam Fornage, PhD; David Green, MD, PhD; Myron Gross, PhD; Gail Davies, PhD; Sarah E Harris, PhD; David C Liewald; John M Starr, MD, PhD; Frances M.K. Williams MBBS, PhD; P.J. Grant, MD, FMed Sci; Timothy D. Spector, MD; Rona J Strawbridge, PhD; Angela Silveira, PhD, Bengt Sennblad, PhD; Fernando Rivadeneira, MD, PhD; Andre G Uitterlinden, PhD; Oscar H Franco, MD, PhD; Albert Hofman, MD, PhD; Jenny van Dongen, Msc; G Willemsen, PhD; Dorret I Boomsma, PhD; Jie Yao, MD, MS; Nancy Swords Jenny, PhD; Talin Haritunians, PhD; Barbara McKnight, PhD; Thomas Lumley, PhD; Kent D Taylor, PhD; Jerome I Rotter, MD; Bruce M Psaty, MD, PhD; Annette Peters, PhD, MPH; Christian Gieger, PhD; Thomas Illig, PhD; Anne Grotevendt, PhD; Georg Homuth, PhD, Henry Völzke, MD; Thomas Kocher, PhD; Anuj Goel, MSc; Maria Grazia Franzosi, PhD; Udo Sedorf, PhD; Robert Clarke, MD, PhD; Maristella Steri, PhD; Kirill V Tarasov, PhD; Serena Sanna, PhD; David Schlessinger, PhD; David J Stott, MD; Naveed Sattar, MD, PhD; Brendan M Buckley, MD, PhD; Ann Rumley, PhD; Gordon D Lowe, MD, DSc; Wendy L McArdle, PhD; Ming-Huei Chen, PhD; Geoffrey H Tofler, MD; Jaejoon Song, MS; Eric Boerwinkle PhD; Aaron R. Folsom, MD, MPH; Lynda M. Rose, MS; Anders Franco-Cereceda, MD, PhD; Martina Teichert, PhD; M Arfan Ikram, MD, PhD; Thomas H Mosley, PhD; Steve Bevan, BSc PhD; Martin Dichgans, MD, PhD; Peter M. Rothwell, MD, PhD; Cathie L M Sudlow, MD, PhD; Jemma C. Hopewell, PhD; John C. Chambers, MD, PhD; Danish Saleheen, MD; Jaspal S. Kooner, MD, PhD; John Danesh, MD, PhD; Christopher P Nelson, PhD; Jeanette Erdmann, PhD; Muredach P. Reilly, MBBCH, MSCE; Sekar Kathiresan, MD; Heribert Schunkert, MD, PhD; Pierre-Emmanuel Morange, MD, PhD; Luigi Ferrucci, MD, PhD; Johan G Eriksson, MD, PhD; David Jacobs, PhD; Ian J Deary, PhD; Nicole Soranzo, PhD; Jacqueline CM Witteman, PhD; Eco JC de Geus, PhD; Russell P. Tracy, PhD; Caroline Hayward, PhD; Wolfgang Koenig, MD; Francesco Cucca, MD, PhD; J Wouter Jukema, MD, PhD; Per Eriksson, PhD; Sudha Seshadri, MD; Hugh S. Markus, DM; Hugh Watkins, MD, PhD; Nilesh J Samani, MD, PhD; VTE consortium; STROKE Consortium; Wellcome Trust Case Control Consortium 2 (WTCCC2); C4D consortium; CARDIoGRAM consortium; Henri Wallaschofski, MD; Nicholas L. Smith, PhD; David Tregouet, PhD; Paul M. Ridker, MD, PhD#; Weihong Tang, MD, PhD#; David P. Strachan, MD#; Anders Hamsten, MD, PhD#; Christopher J. O'Donnell, MD, MPH#

Supplementary Methods:

Cohorts of European descent (see Supplementary Table S1):

The Precocious Coronary Artery Disease Study (PROCARDIS) consists of coronary artery disease (CAD) cases and controls from four European countries (UK, Italy, Sweden and Germany). CAD (defined as myocardial infarction, acute coronary syndrome, unstable or stable angina, or need for coronary artery bypass surgery or percutaneous coronary intervention) was diagnosed before 66 years of age and 80% of cases had a sibling fulfilling the same criteria for CAD. Subjects with self-reported non-European ancestry were excluded. Among the “genetically-enriched” CAD cases, 70% had suffered myocardial infarction (MI).

The Framingham Heart Study (FHS) was started in 1948 with 5,209 randomly ascertained participants from Framingham, Massachusetts, US, who had undergone biannual examinations to investigate cardiovascular disease and its risk factors. In 1971, the Offspring cohort (comprising 5,124 children of the original cohort and the children's spouses) and in 2002, the Third Generation (consisting of 4,095 children of the Offspring cohort) were recruited. FHS participants in this study are of European ancestry. The methods of recruitment and data collection for the Offspring and Third Generation cohorts have been described ¹.

The Women’s Genome Health Study (WGHS) is a prospective cohort of initially healthy, female North American health care professionals at least 45 years old at baseline representing participants in the Women’s Health Study (WHS) who provided a blood sample at baseline and consent for blood-based analyses. The WHS was a 2x2 trial beginning in 1992-1994 of vitamin E and low dose aspirin in prevention of cancer and cardiovascular disease with about 10 years of follow-up. Since the end of the trial, follow-up has continued in observational mode. Additional information related to health and lifestyle were collected by questionnaire throughout the WHS trial and continuing observational follow-up. Detailed information about the study can be found in ².

The SardiNIA study has been previously described ³. Briefly, it is a large population-based study which consists of 6,148 individuals, males and females, ages 14-102 y, that were recruited from a cluster of four towns in the Lanusei Valley of Sardinia. Samples have been characterized for several quantitative traits and medical conditions, including fibrinogen.

The Rotterdam Study is a prospective, population-based cohort study of determinants of several chronic diseases in older adults ⁴. In brief, the study comprised 7,983 inhabitants of Ommoord, a district of Rotterdam in the Netherlands, who were 55 years or over. Subjects are of European ancestry based on their self-report. The baseline examination took place between 1990 and 1993.

The Study of Health in Pomerania (SHIP) is a longitudinal cohort study in West Pomerania, the north-east area of Germany and has been described previously ^{5,6}. From the entire study population of 212,157 inhabitants living in the area, a sample was selected from the population registration offices, where all German inhabitants are registered. Only individuals with German citizenship and main residency in the study area were included. A two-stage cluster sampling method was adopted from the WHO MONICA Project Augsburg, Germany. In a first step, the three cities of the region (with 17,076 to 65,977

inhabitants) and the 12 towns (with 1,516 to 3,044 inhabitants) were selected. Further 17 out of 97 smaller towns (with less than 1,500 inhabitants) were drawn at random. In a second step, from each of the selected communities, subjects were drawn at random, proportional to the population size of each community and stratified by age and gender. Finally, 7,008 subjects aged 20 to 79 years were sampled, with 292 persons of each gender in each of the twelve five-year age strata. In order to minimize drop-outs by migration or death, subjects were selected in two waves. The net sample (without migrated or deceased persons) comprised 6,267 eligible subjects. The SHIP population finally comprised 4,308 participants at baseline (corresponding to a final response of 68.8%).

The Coronary Artery Risk Development in Young Adults (CARDIA) Study is a prospective multicenter study with 5115 adults Caucasian and African American participants of the age group 18-30 years, recruited from four centers. The recruitment was done from the total community in Birmingham, AL, from selected census tracts in Chicago, IL and Minneapolis, MN; and from the Kaiser Permanente health plan membership in Oakland, CA. The details of the study design for the CARDIA study have been previously published⁷. Seven examinations have been completed since initiation of the study in 1985–1986, respectively in the years 0, 2, 5, 7, 10, 15 and 20. Written informed consent was obtained from participants at each examination and all study protocols were approved by the institutional review boards of the participating institutions.

PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a prospective multicenter randomized placebo-controlled trial to assess whether treatment with pravastatin diminishes the risk of major vascular events in elderly. Between December 1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had pre-existing vascular disease or increased risk of such disease because of smoking, hypertension, or diabetes. A total number of 5804 subjects were randomly assigned to pravastatin or placebo. A large number of prospective tests were performed including Biobank tests and cognitive function measurements. A detailed description of the study has been published elsewhere^{8, 9}.

The **Cardiovascular Health Study (CHS)** is a population-based cohort study of risk factors for CHD and stroke in adults ≥ 65 years conducted across 4 field centers¹⁰. The original predominantly Caucasian cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare eligibility lists; subsequently, an additional predominantly African-American cohort of 687 persons was enrolled for a total sample of 5,888. DNA was extracted from blood samples drawn on all participants at their baseline examination in 1989-90.

The Lothian Birth Cohort (LBC) studies, LBC1936 & LBC1921, were ascertained as follows.

The LBC1936 consists of 1,091 relatively healthy individuals assessed on cognitive and medical traits at 70 years of age. They were born in 1936, most took part in the Scottish Mental Survey of 1947, and almost all lived independently in the Lothian region of Scotland (Edinburgh City and surrounding area). A full description of participant recruitment and testing can be found elsewhere.^{11, 12} The LBC1921 cohort consists of 550 relatively healthy individuals, 316 females and 234 males, assessed on cognitive and medical traits at 79 years of age. They were born in 1921, most took part in the Scottish Mental Survey of 1932, and almost all lived independently in the Lothian region in Scotland. A full description of participant recruitment and testing can be found elsewhere.^{11, 13} Ethics permission for the study was

obtained from the Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/56) and from Lothian Research Ethics Committee (LBC1936: LREC/2003/2/29 and LBC1921: LREC/1998/4/183). The research was carried out in compliance with the Helsinki Declaration. All subjects gave written, informed consent.

The MARseille THrombosis Association (MARTHA) project has been previously described¹⁴. Briefly, MARTHA consist in two independent samples of VT patients, named MARTHA08 (N=1,006) and MARTHA10 (N=586). MARTHA patients are unrelated subjects of European origin, with the majority being of French ancestry, consecutively recruited at the Thrombophilia center of La Timone hospital (Marseille, France) between January 1994 and October 2005. All patients had a documented history of VT and free of well characterized genetic risk factors including AT, PC, or PS deficiency, homozygosity for FV Leiden or FII 20210A, and lupus anticoagulant. They were interviewed by a physician on their medical history, which emphasized manifestations of deep vein thrombosis and pulmonary embolism using a standardized questionnaire. The thrombotic events were confirmed by venography, Doppler ultrasound, spiral computed tomographic scanning angiography, and/or ventilation/perfusion lung scan.

The **CROATIA-Split study**, Croatia, is a population-based, cross-sectional study in the Dalmatian City of Split that includes 1000 examinees aged 18-95. Blood samples were collected in 2009 and 2010 along with many clinical and biochemical measures and lifestyle and health questionnaires. A detailed description of the study has been published elsewhere¹⁵.

The **CROATIA-Korcula study**, Croatia, is a family-based, cross-sectional study in the isolated island of Korcula that included 965 examinees aged 18-95. Blood samples were collected in 2007 along with many clinical and biochemical measures and lifestyle and health questionnaires. A detailed description of the study has been published elsewhere¹⁶.

The **CROATIA-Vis study**, Croatia, is a family-based, cross-sectional study in the isolated island of Vis that included 1,056 examinees aged 18-93. Blood samples were collected in 2003 and 2004 along with many clinical and biochemical measures and lifestyle and health questionnaires. A detailed description of the study has been published elsewhere¹⁶.

The **Orkney Complex Disease Study (ORCADES)** was performed in the Scottish archipelago of Orkney and collected data between 2005 and 2011 (mean age 53). Data for 889 participants aged 18 to 100 years from a subgroup of ten islands, were used for this analysis. A detailed description of the study has been published elsewhere¹⁷.

The British 1958 birth cohort (B58C) is a national population sample followed periodically from birth. At age 44-45 years, 9377 cohort members were examined by a research nurse in the home as described previously¹⁸ and non-fasting blood samples were collected with permission for DNA extraction and creation of immortalised cell cultures (<http://www.b58cgene.sgu.ac.uk/collection.php>). DNA samples from unrelated subjects of white ethnicity, with nationwide geographic coverage, were genotyped either by the Wellcome Trust Case Control Consortium (WTCCC)¹⁹, the Type 1 Diabetes Genetics Consortium²⁰ or the GABRIEL consortium²¹.

The MONICA/KORA Augsburg Study consisted of a series of independent population-based epidemiological surveys of participants living in the region of Augsburg, Southern Germany²². All survey participants are residents of German nationality identified through the registration office. The presented data were derived from the third and fourth population-based Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)/ Cooperative Health Research in the Region of Augsburg (KORA) surveys S3 and S4. These cross-sectional surveys covering the city of Augsburg (Germany) and two adjacent counties were conducted in 1994/95 (S3) and 1999/2001 (S4) with 4,856 (S3) and 4,261 (S4) individuals aged 25 to 74 years. S3 was part of the WHO MONICA study. In a follow-up examination of S3 conducted in 2004/05 (MONICA/KORA F3) and of S4 conducted in 2006/08 (MONICA/KORA F4), a number of 3,006 (F3) and 3,080 (F4) subjects participated. All participants underwent standardized examinations including blood withdrawals for plasma and DNA. For the MONICA/KORA genome-wide association study, a number of 1,644 and 1,814 subjects were selected from F3 and F4 samples²³. After excluding subjects with no albumin measurements available, the final populations for the MONICA/KORA data comprised 1,523 (S3/F3) and 1,788 (S4/F4) subjects.

The Aging in the Chianti Area (InCHIANTI) study is a population-based epidemiological study aimed at evaluating the factors that influence mobility in the older population living in the Chianti region in Tuscany, Italy. The details of the study have been previously reported²⁴. Briefly, 1616 residents were selected from the population registry of Greve in Chianti (a rural area: 11,709 residents with 19.3% of the population greater than 65 years of age), and Bagno a Ripoli (Antella village near Florence; 4,704 inhabitants, with 20.3% greater than 65 years of age). The participation rate was 90% (n=1453).

The **TwinsUK** cohort was derived from the UK adult twin registry based at King's College London (www.twinsUK.ac.uk). These unselected twins have been recruited from the general population through national media campaigns in the United Kingdom and shown to be comparable to age-matched population singletons in terms of disease-related and lifestyle characteristics²⁵. Informed consent was obtained from all participants and the study was approved by the St. Thomas' Hospital Ethics Committee.

The Helsinki Birth Cohort Study (HBCS) is composed of 8 760 individuals born between the years 1934-44 in one of the two main maternity hospitals in Helsinki, Finland. Between 2001 and 2003, a randomly selected sample of 928 males and 1 075 females participated in a clinical follow-up study with a focus on cardiovascular, metabolic and reproductive health, cognitive function and depressive symptoms. Detailed information on the selection of the HBCS participants and on the study design can be found elsewhere^{26, 27}. Research plan of the HBCS was approved by the Institutional Review Board of the National Public Health Institute and all participants have signed an informed consent.

The Netherlands Twin Registry (NTR): Between January 2004 and July 2008, 9,530 participants from 3,477 families registered in the NTR were visited at home between 7:00 and 10:00 am for collection of blood samples. Fertile women were bled on day 2–4 of the menstrual cycle, or in their pill-free week. Body composition was measured and information about physical health and lifestyle (e.g. smoking and drinking behavior, physical exercise, medication use) was obtained. For more detailed information about the methodology of the NTR Biobank study, see²⁸. Valid GWA data were available for 2490 individuals.

The Atherosclerosis Risk in Communities (ARIC): The Atherosclerosis Risk in Communities (ARIC) Study recruited 15,792 adults aged 45 to 64 years in 1987 through 1989 by probability sampling from Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland²⁹. The Jackson sample comprised African Americans only; the other three samples represent the ethnic mix of their communities. Extensive information was collected at baseline on cardiovascular risk factors. The ARIC study was approved by the institutional review board of each field center institutes and participants gave informed consent including consent for genetic testing. In this study we included only European American and African American participants.

Multi-Ethnic Study of Atherosclerosis (MESA): The MESA is a cohort study designed to investigate the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA comprises a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are Caucasian, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent³⁰. Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles.

Cohorts of African American and Hispanic descent (see Supplementary Table S2)

The Atherosclerosis Risk in Communities (ARIC): See information in the *Cohorts of European descent* section.

The Genetic Study of Atherosclerosis Risk (GeneSTAR) is an ongoing prospective study begun in 1983 to determine environmental, phenotypic, and genetic causes of premature cardiovascular disease³¹. Participants came from European and African American families identified from probands with a premature coronary disease event prior to 60 years of age who were identified at the time of hospitalization in any of 10 Baltimore area hospitals. Their apparently healthy 30-59 year old siblings without known CAD were recruited and underwent phenotypic measurement and characterization between 1983 and 2006; offspring of the siblings and probands, as well as the co-parent of these offspring, were recruited and assessed between 2003 and 2006.

The Women's Health Initiative (WHI) is one of the largest (n=161,808) studies of women's health ever undertaken in the U.S [1]. There are two major components of WHI: (1) a Clinical Trial (CT) that enrolled and randomized 68,132 women ages 50 – 79 into at least one of three placebo-control clinical trials (hormone therapy, dietary modification, and calcium/vitamin D); and (2) an Observational Study (OS) that enrolled 93,676 women of the same age range into a parallel prospective cohort study³². A diverse population including 26,045 (17%) women from minority groups were recruited from 1993-1998 at 40 clinical centers across the U.S. Of the CT and OS minority participants enrolled in WHI, 12,157 (including 8,515 self identified African American and 3,642 self identified Hispanic subjects) who had consented to genetic research were eligible for the WHI SHARe GWAS project. DNA was

extracted by the Specimen Processing Laboratory at the Fred Hutchinson Cancer research Center (FHCRC) using specimens that were collected at the time of enrollment. Only African American participants with fibrinogen measured at baseline were included in this analysis.

Cleveland Family Study (CFS): The CFS is a family-based longitudinal study designed to study the risk factors for sleep apnea.³³ Participants include first-degree or selected second-degree relatives of a proband with either laboratory diagnosed obstructive sleep apnea or neighborhood control of an affected proband. In total, 2,534 individuals (46% African American) from 352 families were studied on up to 4 occasions over a period of 16 years (1990-2006). The initial aim of the study was to quantify the familial aggregation of sleep apnea. Over time, the aims were expanded to characterize the natural history of sleep apnea, sleep apnea outcomes, and to identify the genetic basis for sleep apnea.

Phenotyping methods (see Supplementary Tables S1 and S2)

PROCARDIS: Plasma fibrinogen concentrations for the Procardis_clauss sub-sample were measured in fasting citrate plasma samples by the Clauss method using the IL Test Fibrinogen C kit and IL Test Calibration Plasma, on the ACL-9000 coagulometer (all from Instrumentation Laboratory Spa, Milan, Italy). The inter- assay CV was 7% (n=106). For the Procardis_immunonephelometric, fibrinogen was measured in EDTA plasma samples using Dade Behring reagents on the Dade-Behring Nephelometer II analyzer (Dade-Behring, Marburg, Germany). The inter-assay CV was 5.5%.

FHS: Fibrinogen levels were measured using the Clauss method³⁴ in the offspring and the third-generation subjects, and a modified method of Ratnoff and Menzie in the original cohort subjects³⁵.

WGHS: Fibrinogen was measured by a mass-based immunoturbidimetric assay (DiaSorin) with reproducibility of 5.20% and 3.99% at concentrations of 0.99 and 2.74 g/L respectively.

SARDINIA: The study measured fibrinogen levels using the Clauss method³⁴.

RS: Fibrinogen levels were derived from the clotting curve of the prothrombin time assay using Thromborel S as a reagent on an automated coagulation laboratory 300 (ACL 300, Instrumentation Laboratory, Zaventem, Belgium).

SHIP: A non-fasting blood sample was drawn from the antecubital vein in the supine position and immediately analyzed or stored at -80°C. Plasma fibrinogen concentrations were assayed according to Clauss³⁴ using an Electra 1600 analyzer (Instrumentation Laboratory, Barcelona, Spain). Coagulation time is measured and transferred into the result in g/L by applying a reference curve calculated in the laboratory. The assay proves linearity between 0.7 – 7 g/L. The analytical sensitivity of the assay was 0.7 g/L. Internal quality control measures were performed daily using two levels of manufacturers' control materials. External quality control measures were performed on a regular basis by participating in analysis programs. The inter-assay coefficients of variation were 4.61 % at low levels (mean value = 0.95 g/L) and 1.82% at high levels (mean value = 3.22 g/L) of control material.

CARDIA: Total fibrinogen concentration at the Y7 examination was determined at the University of Vermont using immunonephelometry (BNII Nephelometer 100 Analyzer; Dade Behring, Deerfield, IL, USA). The amount of immuno-reactive fibrinogen present in the sample was quantitatively determined by light scatter intensity. The immunoassay was calibrated using reference plasma, and the results reported in mg dL⁻¹. The intra-assay and inter-assay coefficient of variation (CVs) for the immunoassay were 2.7% and 2.6%, respectively.

PROSPER: Fibrinogen levels were measured by the Clauss method³⁴ using aMDA180 coagulometer (Trinity Biotech; calibrant 9th British standard National Institute for Biological Standards and Control).

CHS: After an 8-12-h fast, CHS participants underwent phlebotomy by atraumatic venipuncture with a 21-gauge butterfly needle connected to a Vacutainer (Becton Dickinson, Rutherford, NJ) outlet via a Luer adaptor³⁶. For fibrinogen determination, an additional citrate-containing tube was processed at 4° C. The study measured fibrinogen levels using the Clauss methods.

LBC: Fibrinogen levels were measured using HemosIL™ based on the Clauss method. No exclusions were applied. Outliers were removed (>3.3SD). Plasma fibrinogen was in g/L, natural log transformed.

MARTHA: Blood samples were collected by antecubital venipuncture into Vacutainer® tubes 0.105 M trisodium citrate (ratio 9:1, Becton Dickinson) for the coagulation test and the thrombin generation assay. Platelet-poor plasma (PPP) was obtained after double centrifugation of citrated blood (3000 g for 10 min at 25°C) and kept frozen at -80°C until analysis. Fibrinogen levels were measured using the Clauss³⁴ method on STAR automatic coagulometer.

CROATIA-ORCADES: All 4 studies used the Clauss method for measuring plasma fibrinogen.

B58BC: Details of the blood collection, fibrinogen measurement and covariate adjustment have been described elsewhere³⁷. In brief, fibrinogen was measured by the Clauss method³⁴ using an MDA 180 coagulometer (Biomerieux, Basingstoke, UK).

KORA: Fibrinogen was determined by an immunonephelometric method (Dade Behring Marburg GmbH, Marburg, Germany) on a Behring Nephelometer II analyzer.

InCHIANTI: Overnight fasted blood samples were used for genomic DNA extraction, and measurement of fibrinogen. Plasma fibrinogen concentrations were measured by the Clauss method³⁴ using STA fibrinogen assay (Diagnostic Stago, Roche Diagnostics, France). The intra- and inter-assay CV was 4.1%.

Twins UK: Fasting blood samples was taken from samples into 0.13 trisodium citrate containers (Becton Dickinson, Oxford, United Kingdom) at room temperature, centrifuged at 2560g for 20 minutes to obtain platelet-poor plasma within 1 hour of collection and stored at -40°C until analysis. Fibrinogen levels were determined using the Clauss method³⁸.

HBCS: Fibrinogen levels were measured using the Clauss method³⁹ with an electrical impedance end point. Plasma fibrinogen was measured in g/L and was natural log transformed to attain normality.

NTR: Fibrinogen was measured in a 4.5 ml CTAD tube that was stored during transport in melting ice and upon arrival at the laboratory, centrifuged for 20 minutes at 2000x g at 4° C, after which citrated plasma was harvested, aliquoted (0.5 ml), snapfrozen in dry ice, and stored at -30° C. Fibrinogen levels were determined on a STA Compact Analyzer (Diagnostica Stago, France), using STA Fibrinogen (Diagnostica Stago, France).

ARIC: Fibrinogen was measured at baseline in the entire ARIC cohort after an 8-hour fasting period. Circulating plasma fibrinogen was measured by the Clauss clotting rate method³⁹. Participants whose fibrinogen measurement was off 6SD from the mean were also excluded.

MESA: Fasting blood samples were collected, processed and stored using standardized procedures³⁶. Fibrinogen antigen was measured using the BNII nephelometer (N Antiserum to Human Fibrinogen; Dade Behring Inc., Deerfield, IL). The assay was performed at the Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, VT). Intra- and inter-assay analytical coefficients of variation were 2.7% and 2.6%, respectively.

GeneSTAR: Blood was obtained from venipuncture and collected into vacutainer tubes containing 3.2% sodium citrate. Plasma fibrinogen was measured using a modified Clauss method on an automated optical clot detection device (Dade-Behring, Newark, DE). Excess thrombin was added to citrated plasma, and the time needed for clot formation was recorded. This clotting time was then compared with that of a standardized fibrinogen preparation.

WHI: Blood samples were collected from all participants at baseline and stored at -70° Celsius. Fibrinogen was measured using a turbidometric fibrinogen clot rate assay (MLA ELECTRA 1400C; Medical Laboratory Automation Inc., Mt. Vernon, NY).

CFS: Fibrinogen levels were assayed at the University of Vermont Laboratory for Clinical Biochemistry Research using fasting blood samples collected at an examination performed between 2001-2006 (STA-R automated coagulation analyzer, Diagnostica Stago; Parsippany, NJ), which used the clotting method developed by Clauss³⁹.

Genotyping methods (see Supplementary Table S3 and S4)

PROCARDIS: PROCARDIS was genotyped using Illumina Human 1M and 610K quad arrays on a total of 6000 patients with CAD and 7,500 control subjects. Genotype quality control excluded SNPs with a call rate <95%, MAF <0.01, HWE $p < 10^{-6}$. After quality filtering, SNPs were imputed to HapMap22, build 36, using MACHv1.0.16. After imputation, a total of 2,543,888 remained available for analyses.

FHS: Genotyping was carried out as a part of the SNP Health Association Resource project using the Affymetrix 500K mapping array (250K Nsp and 250K Sty arrays) and the Affymetrix 50K supplemental

gene focused array on 9274 individuals. Genotyping resulted in 503 551 SNPs with successful call rate > 95% and HWE $P > 1E-6$ on 8481 individuals with call rate > 97%. Imputation of ~2.5 million autosomal SNPs in HapMap with reference to release 22 CEU sample was conducted using the algorithm implemented in MACH. The final population for fibrinogen analysis included 7022 individuals (original cohort, $n=383$; offspring, $n=2806$; third generation, $n=3833$).

WGHS: Genotyping in the WGHS sample was performed using the HumanHap300 Duo “+” chips or the combination of the HumanHuman300 Duo and iSelect chips (Illumina, San Diego, CA) with the Infinium II protocol. In either case, the custom SNP content was the same; these custom SNPs were chosen without regard to minor allele frequency (MAF) to saturate candidate genes for cardiovascular disease as well as to increase coverage of SNPs with known or suspected biological function, e.g. disease association, non-synonymous changes, substitutions at splice sites, etc. For quality control, all samples were required to have successful genotyping using the BeadStudio v. 3.3 software (Illumina, San Diego, CA) for at least 98% of the SNPs. A subset of 23,294 individuals were identified with self-reported European ancestry that could be verified on the basis of multidimensional scaling analysis of identity by state using 1443 ancestry informative markers in PLINK v. 1.06. In the final dataset of these individuals, SNPs were retained with $MAF > 1\%$, successful genotyping in 90% of the subjects, and deviations from Hardy-Weinberg equilibrium not exceeding $P=10^{-6}$ in significance. Among the final 23,294 individuals of verified European ancestry, genotypes for a total of 2,608,509 SNPs were imputed from the experimental genotypes and LD relationships implicit in the HapMap r. 22 CEU samples.

SardiNIA: Genotyping started on 2004, and different subset of samples have been genotyped with different SNP arrays. Specifically, 1,412 were genotyped with the 500K Affymetrix Mapping Array set; 3,329 with the 10K Mapping Array set, with 436 individuals genotyped with both arrays; 1,097 individuals with the 6.0 Affymetrix chip, of which 1,004 and 66 of those were typed with the 10K and 500K chips respectively. Quality controls filters for the 500K and 10K array have been previously described (Scuteri et al Plos Genetics 2007; Sanna et al Nat Gen 2008). For the Affymetrix 6.0 chip, we removed SNPs with call rate <95%, $MAF < 1\%$ and $HWE_{pvalue} < 10^{-6}$ (Naitza et al Plos Genet 2011, submitted). We also discarded SNPs that showed an excess of mendelian errors and SNPs in common with the 500K showing an excess of discordant genotypes (>3 over 66 samples).

After performing quality control checks and merging genotypes from the three gene chip platform, we used 731,209 QCed autosomal markers to estimate genotypes for all polymorphic SNPs in the CEU HapMap population (release 22, The International HapMap Consortium, 2007) in the individuals genotyped with the 500K Array and the 6.0 Affymetrix chip separately, using the MaCH software (Li et al 2009, <http://www.sph.umich.edu/csg/abecasis/mach/>). Taking advantage of the relatedness among individuals in the SardiNIA sample, we carried out a second round of computational analysis to impute genotypes at all SNPs in the individuals who were genotyped only with the Affymetrix Mapping 10K Array, being mostly offspring and siblings of the individuals genotyped at high density. At this second round of imputation, we focused on the SNPs for which the imputation procedure predicted $r^2 > 0.30$ between true and imputed genotypes and for which the inferred genotype did not generate an excess of Mendelian Errors. The within-family imputation procedure is implemented in Merlin software (Abecasis et al., 2002; Chen W-M & Abecasis G-R, 2007). Overall, a total of 2,325,920 autosomal SNPs were selected for GWAS.

Due to computational constraints, we divided large pedigrees into sub-units with “bit-complexity” of 21 or less (typically, 25-30 individuals) before analysis.

The CROATIA-Vis study genotyping used the Illumina HAP300v1 SNP chip. Genotype quality control excluded SNPs with a call rate <95%, MAF <0.01, HWE $p < 10^{-6}$. Analysis was performed using GenABEL with first 3 principal components accounting for population stratification and “mmscore” option to account for relationships. SNPs were imputed to HapMap22, build 36, using MACHv1.16. and GenABEL derived residuals were analysed using ProbABEL.

RS: Genotyping was conducted using the Illumina 550K array. SNPs were excluded for minor allele frequency $\leq 1\%$, Hardy-Weinberg equilibrium (HWE) $p < 10^{-5}$, or SNP call rate $\leq 90\%$ resulting in data on 530,683 SNPs. Imputation was done with reference to HapMap release 22 CEU using the maximum likelihood method implemented in MACH.

The **SHIP** samples were genotyped using the Affymetrix Human SNP Array 6.0. Hybridisation of genomic DNA was done in accordance with the manufacturer’s standard recommendations. The genetic data analysis workflow was created using the Software InforSense. Genetic data were stored using the database Caché (InterSystems). Genotypes were determined using the Birdseed2 clustering algorithm. For quality control purposes, several control samples were added. On the chip level, only subjects with a genotyping rate on QC probesets (QC callrate) of at least 86% were included. All remaining arrays had a sample callrate > 92%. The overall genotyping efficiency of the GWA was 98.55 %. Imputation of genotypes in SHIP was performed with the software IMPUTE v0.5.0 based on HapMap II.

CARDIA (European): Study samples from were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, California); only participants of European descent were included in the GWAS analyses. Samples with high missing rate, cryptic IBS, and population stratification outliers were excluded from the analysis. Genotyping was completed for 1720 individuals with a sample call rate $\geq 98\%$. A total of 578,568 SNPs passed quality control (MAF $\geq 2\%$, call rate $\geq 95\%$, HWE $\geq 10^{-4}$) and were used for imputation. For this study, complete genotype and phenotype information were available for 1435 individuals.

PROSPER/PHASE: A whole genome wide screening has been performed in the sequential PHASE project with the use of the Illumina 660K beadchip. Of 5763 subjects DNA was available for genotyping. After QC (call rate <95%) 557,192 SNPs and 5244 subjects were left for analysis. The SNPs were imputed to 2.5 million SNPs based on the HAPMAP build 36 with MACH imputation software.

CHS: In 2007-2008, genotyping was performed on CHS European-ancestry participants at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system on 3980 CHS participants who were free of CVD at baseline, consented to genetic testing, and had DNA available for genotyping. In 2010, the African-ancestry were genotyped at the same lab using the Illumina HumanOmni1-Quad_v1 BeadChip system. Genotypes were called using the Illumina GenomeStudio software.

LBC: A detailed description of the genotyping method is available elsewhere⁴⁰. In brief, genotyping was performed on Illumina Human 610-Quadv1 chip on blood-extracted DNA. Standard quality control measures were applied including the following thresholds: call rate ≥ 0.98 , minor allele frequency ≥ 0.01 , and Hardy-Weinberg Equilibrium test with $P \geq 0.001$. ~ 2.5 M common SNPs included in HapMap, using the HapMap phase II CEU data as the reference sample were imputed. NCBI build 36 (UCSC hg18) was used and genotype data were imputed using MACH software. Prior to imputation SNPs were removed that diverged from HWE with a significance $p < 1 \times 10^{-3}$ and SNPs with a minor allele frequency < 0.01 . The respective SNP call and sample call rates were 0.98 and 0.95. 2,543,887 SNPs were imputed.

MARTHA: The MARTHA08 study sample was typed with the Illumina Human610-Quad Beadchip while the MARTHA10 sample was typed with the Illumina Human660W-Quad Beadchip. SNPs showing significant ($P < 10^{-5}$) deviation from Hardy-Weinberg equilibrium, with minor allele frequency (MAF) less than 1% or genotyping call rate $< 99\%$, in each study were filtered out.

After the filtering, 494,721 and 501,773 autosomal SNPs were left for association analysis and further used for imputing ~ 2.5 million autosomal SNPs according to the CEU HapMap release 21 reference dataset. The imputation was performed using MACH v1.0.16.

Individuals with genotyping success rates less than 95% were excluded from the analyses, as well as individuals demonstrating close relatedness as detected by pairwise clustering of identity by state distances (IBS) and multi-dimensional scaling (MDS) implemented in PLINK software⁴¹. Non-European ancestry was also investigated using the Eigenstrat program (Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006, 38:904-909) leading to the final selection of 972 and 570 patients left for analysis in MARTHA08 and MARTHA10, respectively.

The **CROATIA-Split** study genotyping used the Illumina HAP370CNV SNP chip. Genotype quality control excluded SNPs with a call rate $< 98\%$, MAF < 0.01 , HWE $p < 10e-6$. Analysis was performed using GenABEL with first 3 principal components accounting for population stratification and “mmscore” option to account for relationships. SNPs were imputed to HapMap22, build 36, using MACHv1.16. and GenABEL derived residuals were analysed using ProbABEL

The **CROATIA-Korcula** study genotyping used the Illumina HAP370CNV SNP chip. Genotype quality control excluded SNPs with a call rate $< 98\%$, MAF < 0.01 , HWE $p < 10e-6$. Analysis was performed using GenABEL with first 3 principal components accounting for population stratification and “mmscore” option to account for relationships. SNPs were imputed to HapMap22, build 36, using MACHv1.16. and GenABEL derived residuals were analysed using ProbABEL

The **ORCADES** study study genotyping used the Illumina HAP300v2 SNP chip. Genotype quality control excluded SNPs with a call rate $< 98\%$, MAF < 0.01 , HWE $p < 10e-6$. Analysis was performed using GenABEL with first 3 principal components accounting for population stratification and “mmscore” option to account for relationships. SNPs were imputed to HapMap22, build 36, using MACHv1.16. and GenABEL derived residuals were analysed using ProbABEL

MONICA/KORA: Genotyping for F3 was performed using Affymetrix 500K Array Set consisting of two chips (Sty I and Nsp I). The F4 samples were genotyped with the Affymetrix Human SNP Array 6.0.

Hybridisation of genomic DNA was done in accordance with the manufacturer's standard recommendations. Genotypes were determined using BRLMM clustering algorithm (Affymetrix 500K Array Set) or Birdseed2 clustering algorithm (Affymetrix Array 6.0). For quality control purposes, we applied a positive control and a negative control DNA every 48 samples (F3) or 96 samples (F4). On chip level only subjects with overall genotyping efficiencies of at least 93% were included. In addition the called gender had to agree with the gender in the MONICA/KORA study database. Imputation of genotypes was performed using maximum likelihood method with the software MACH v1.0.9 (F3) and MACH v1.0.15 (F4).

INCHIANTI: Illumina Infinium HumanHap 550K SNP arrays were used for genotyping⁴². Genotyping was completed for 1210 subjects with a sample call rate $\geq 97\%$, heterozygosity rates ≥ 0.3 and correct sex specification. 495,343 autosomal SNPs that passed quality control (MAF $\geq 1\%$, completeness $\geq 99\%$, HWE $\geq 10^{-4}$) were used for imputation. The HapMap CEU sample (build 36) was used as a reference to impute approximately 2.5 million SNPs using MACHv.1.16. Association analysis was conducted using MERLIN software.

Twins UK: Genotyping of the TwinsUK dataset was done with a combination of Illumina arrays (HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M). Intensity data for each of the three arrays were pooled separately (with 1M-Duo and 1.2MDuo 1M pooled together) and genotypes were assigned using the Illuminus calling algorithm⁴³. We applied similar quality control criteria to each dataset and merged them⁴⁴. Imputation was performed using the IMPUTE v2 using two reference panels, P0 (HapMap2, rel 22, combined CEU+YRI+ASN panels) and P1 (610k+, including the combined HumanHap610k and 1M reduced to 610k SNP content).

HBSCS: DNA was extracted from blood samples and genotyping was performed with the modified Illumina 610k chip by the Wellcome Trust Sanger Institute, Cambridge, UK according to standard protocols. Genomic coverage was extended by imputation using the HapMap phase II CEU data as the reference sample and MACH software.

NTR: Three platforms were used to genotype the data : AFFY/Perlegen 660K, Illumina 370K and Illumina 660K. Per platform the quality control inclusion thresholds for SNPs were MAF $> 1\%$, HWE > 0.00001 , call rate $> 95\%$ and $0.30 < \text{Heterozygosity} < 0.35$. Samples were excluded from the data if their expected sex and IBD status did not match, or if the genotype missing rate was above 10%. For each platform all SNPs were aligned to the positive strand of the Hapmap 2 Build 36 release 24 CEU reference set. The alignment was checked using individuals and family members tested on multiple platforms. SNPs were excluded per platform if allele frequencies differed more than 15% with the reference set and/or the other platforms. The data of the three chips were then imputed with the IMPUTE program on Hapmap 2 build 36rel24 (J. Marchini). From the imputed sets, SNPs were removed if the MAF had a difference larger than 0.15 between subsets (same reference alleles). The remaining SNPs were merged into one single set. Afterwards, bad imputed SNPs were removed based on HWE < 0.00001 , proper info < 0.40 and MAF $< 1\%$.

ARIC (European): Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) at the Broad Institute of Harvard and MIT. Exclusions at

individual level included disallowing DNA use, unintentional duplicates with higher missing genotype rates, suspected mixed/contaminated samples, scans from one problem plate, samples with a mismatch between called and phenotypic sex, samples with genotype mismatch with 39 previously genotyped SNPs, suspected first-degree relative of an included individual, and genetic outliers based on average IBS statistics and principal components analysis using EIGENSTRAT⁴⁵. SNPs were excluded due to no chromosome location, being monomorphic, call rate <95%, or HWE- $p < 10^{-6}$ for SNPs with MAF>0.05. In addition, imputation to approximately 2.5 million autosomal SNPs identified in HapMap Phase II CEU samples was performed using MACH v1.0.16⁴⁶. SNPs that met the following criteria were included in the imputation: MAF $\geq 1\%$, call rate $\geq 95\%$, and HWE- $p \geq 10^{-5}$.

MESA: Caucasian, Hispanic, and Chinese American participants were genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) at the Affymetrix Research Services Lab. 6880 samples passed initial genotyping QC. African American samples were genotyped at the Broad Institute of Harvard and MIT as part of the CARE project. Affymetrix performed wet lab hybridization assay, and plate-based genotype calling using Birdseed v2. Sample QC was based on call rates and contrast QC (cQC) statistics. Broad performed similar QC for CARE sample. Additional sample and SNP QC were carried out at University of Virginia, including sample call rate, sample cQC, and sample heterozygosity by race at the sample level; Outlier plates checking by call rate, median cQC or heterozygosity at plate level. Four samples were removed due to low call rate (<95%). Cryptic sample duplicates or unresolved cryptic duplicates were dropped. Unresolved gender mismatches were also dropped. At the SNP level, we excluded monomorphic SNPs across all samples; SNPs with missing Rate was > 5% or observed heterozygosity > 53% were also excluded. Additional genotypes were imputed separately in each ethnic group using the program IMPUTE2. HapMap CEU was used as the reference population for CAU sample, while a combined CEU+YRI reference panel was used for the African-American cohorts, and a combined CEU+YRI+CHB+JPT reference panel was used for the Hispanic sample.

Candidate Gene Association Resource (CARE) AA Cohorts- ARIC, CARDIA, CFS, and MESA: African American samples in ARIC, CARDIA, CFS, and MESA were genotyped as part of the CARE at the Broad Institute of Harvard and MIT using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affy6.0). Two methods of DNA quality control metrics were assessed on the samples prior to the genome scan. First, quantity of double stranded DNA was assessed using PicoGreen® (Molecular Probes, Oregon, USA). Next, to confirm sample identity, a set of 24 markers including a gender confirmation assay were genotyped using the Sequenom platform to serve as a genetic fingerprint. Each of these 24 SNPs are also on the Affy6.0 array and served as a cross-platform sample verification. Genotypes were called using Birdseed v1.33.^{47, 48} Quality controls steps were performed using the software PLINK,⁴¹ EIGENSTRAT,⁴⁵ and PREST-Plus.⁴⁹ Imputation was performed using MACH 1.0.16 (<http://www.sph.umich.edu/csg/abecasis/MaCH/>) with a combined CEU+YRI as the reference panel. Comparison of genotypes for SNPs that were imputed in the GWAS and also genotyped on the CARE candidate gene SNP array estimated an allelic concordance rate of ~95.6% between genotyping and imputation for those SNPs. This rate is comparable to rates calculated for individuals of African descent

imputed with the HapMap 2 YRI individuals.⁵⁰ Imputation results were filtered at an RSQ_HAT threshold of 0.3 and a minor allele frequency threshold of 0.01.

GeneSTAR: The Illumina 1Mv1_c platform was used for genotyping, and MACH v1.0.16 was used to impute to 2.5 million SNPs in HapMap II.

WHI: Genotyping was done at Affymetrix Inc on the Affymetrix 6.0 array, using 2 ug DNA at a concentration of 100 ng/ul. 2% additional samples were genotyped as blind duplicates. We first removed samples that had call rate below 95%, that were duplicates of subjects other than monozygotic twins, or that had a Y-chromosome. SNPs that were located on the Y chromosome or were Affymetrix QC probes (not intended for analysis) were excluded (n=3280). We also flagged SNPs that had call rates, calculated separately for African Americans and Hispanics, below 95% and concordance rates below 98%, leaving us 871,309 unflagged SNPs. We computed IBD coefficients between all pairs of subjects using a random subset of 100,000 SNPs from autosomal chromosomes. A more thorough confirmatory analysis using a pairwise kinship coefficient estimator was performed separately for African Americans and Hispanics that validated these relationships and identified half-siblings. We were left with 8,412 unique African-American subjects, with an average call rate of 99.8% over the unflagged SNPs. We analyzed 188 pairs of blind duplicate samples. The overall concordance rate was 99.8% (range 94.5-100% over all samples, 98.3%-100% over samples with call rate >98%, 98.1-100% over unflagged SNPs).

Imputation in African-Americans was performed using MaCH 1.0.16. Individuals with pedigree relatedness or cryptic relatedness ($\pi_{\text{hat}} > 0.05$) were filtered prior to imputation. SNPs with MAF $\geq 1\%$, call rate $\geq 97\%$ and HWE $P \geq 10^{-6}$ were used for imputation. A combined CEU+YRI reference panel from HapMap phase 2 (release 22, build 36) was used. A randomly selected subset of individuals from each cohort sample was used to generate recombination and error rate estimates. These rates were then used to estimate genotype dosages in all sampled individuals across the entire reference panel for over 2 million SNPs. Imputation results were filtered using a minimum imputation quality score, indicated by the RSQ_HAT estimate in MaCH of >0.5 and a MAF threshold of $>1\%$. On a small test sample (2% of the markers on three chromosomes), the average R-squared was 0.88, with an allelic discordance rate of 2.3%.

Statistical analyses in European samples

Twenty-eight cohorts contributed to the GWA study meta-analysis of European-ancestry individuals including a total of 57,813 individuals:

the Atherosclerosis Risk in Communities Study (ARIC, n=9,256), the British 1958 Birth Cohort (B58BC, n=6,085), CARDIA (n=1,435), the Cardiovascular Health Study (CHS, n=3,227), the Framingham Heart Study (FHS, n=7,022), the Helsinki Birth Cohort Study (HBCS, n=1,401), InChianti, n=1,196), KOCULA, n=801), LBC1921 (n=486), LBC1936 (n= 989), the Marseille Thrombosis Association (MARTHA08, n=613 and MARTHA10, n=374), MESA, n=2,404), the MONICA/KORA study (n=1,523+1788), NTR n=2,490, ORCADES (n=883), the Precocious Coronary Artery Disease Study (PROCARDIS) cases (n=3,489+1168) and controls (n=2,224), PROSPER (n=5,104), RSI (n=2,433), SardinIA (n=4,691), SHIP (n=3,841), SPLIT (n=492), TwinsUK (n=2,058), VIS (n=882), and Woman's Genome Health Study (WGHS, n=23,080).

Fibrinogen levels were natural log-transformed in all cohorts except for Twins UK. Association of SNPs with fibrinogen levels was tested using a linear regression analysis assuming an additive genetic model in which allele dosage (0 to 2 copies of the minor allele) of genotyped or imputed SNPs, using MACH2QTL (LBC, MARTHA), ProbABEL 0.1-3⁵¹ (WGHS, B58C, KORA, PROSPER, CROATIA-Vis, CROATIA-Korcula, CROATIA-Split, ORCADES, RS, CARDIA, HBCS, ARIC), Stata (PROCARDIS, B58C), SAS (KORA), MERLIN (InCHIANTI, SardinIA), QUICKTEST v0.95 (<http://toby.freeshell.org/software/quicktest.shtml>) (SHIP), SNPtest v.1.2 (NTR) and PLINK⁴¹ (MARTHA, HBCS) softwares, incorporating dosage information and including age and sex as covariates in the model. TwinsUK used a score test and variance components methods implemented in MERLIN to account for zygosity and family structure. The B58C adjusted for sex, laboratory batch, time of day, month of examination, and postal delay. ARIC also adjusted for center. Population stratification was accounted for by further adjustment for principal components, multidimensional scaling or country when necessary (MARTHA, PROCARDIS, PROSPER, CROATIA-Vis, CROATIA-Korcula, CROATIA-Split and ORCADES). Family structure was accounted for in FHS, PROCARDIS, CROATIA-Vis, CROATIA-Korcula, CROATIA-Split, and ORCADES. In FHS, a linear mixed effects model was used with a fixed additive effect for the SNP genotype, fixed covariate effects, random family-specific additive residual polygenic effects to account for within family correlations, and a random environment effect⁵². Individuals using anticoagulant therapy were excluded in B58C, PROCARDIS, MARTHA08 and MARTHA10).

Samples with high missing rate and cryptic IBS were excluded from the analysis. Participants who used warfarin or whose fibrinogen measurement was off 6SD from the mean were excluded in ARIC. Subjects were excluded when values of fibrinogen exceeded 6 pg/ml or when they were using anti-inflammatory medication or medication influencing the HPA-axis at the time of sampling in NTR.

Genomic control correction was applied to the individual cohorts. Lambda values for the individual GWAS were: PROCARDIS_Cases 1.008; PROCARDIS_Cases.imm 1.016; PROCARDIS_Controls 1.011; FHS 1.018; WGHS 1.066; SardinIA 0.977; RS 0.998; SHIP 1.034; CARDIA 1.001; PROSPER_PHASE 1.021; CHS 1.027; LBC1921 1.002; LBC1936 1.008; MARTHA08 0.977; MARTHA10 0.977; VIS 1.006; KORCULA 1.001; SPLIT 1.005; ORCADES 1.006; B58C 1.034; MONICA_KORA_F3 1.018; MONICA_KORA_F4 1.013; InCHIANTI 1.018; TwinsUK 0.977; NTR 1.023; HBCS 1; ARIC 1.034; MESA 1.001. The overall measure of genomic inflation from the meta-analysis was $\lambda=1.147$. Additional meta-analyses were also performed in cohorts grouped by method used for plasma fibrinogen determination (immunonephelometric or activity method), and heterogeneity P values were calculated using METAL.

GWA analyses were repeated in each of the European-ancestry samples using the same model as in discovery, with additional conditioning on the SNP with the lowest *P*-value (the “lead SNP”) within each genome-wide significant locus from the discovery meta-analysis. Conditional meta-analyses was performed in 21 European-ancestry cohorts, including more than 76,600 individuals, and individual cohort results were subsequently meta-analyzed as described above.

Statistical analyses in non-European samples:

For the validation in other ethnicities, allelic dosage at each SNP was used as the independent variable, adjusted for age and sex. Analyses were performed using the snpMatrix (WHI) or GWAF (GeneSTAR)

analysis packages in R. Samples with high missing rate, cryptic IBS, and population stratification outliers were excluded from the analysis. GeneSTAR accounted for familial correlations and excluded samples identified with gender discrepancy, Mendelian inconsistency rate > 5%, or as EIGENSTRAT outliers. To adjust for population stratification, 10 principal components were also incorporated as covariates in the regression models (WHI). For the four CARE AA Cohorts (ARIC, CARDIA, CFS, and MESA), measurement for fibrinogen was regressed on age, gender, and cohort-specific covariates in a linear regression model and residuals were output for use in the genetic analysis. For all CARE cohorts but CFS, the genetic analysis was performed in PLINK⁴¹ using a linear regression model under the assumption of an additive genetic effect. Dosage information of directly measured and imputed genotypes was analyzed in the regression implemented in PLINK with the adjustment for the first ten principal components. For CFS, the family structure was modeled in the genetic association tests by linear mixed effects (LME) models implemented in R.⁵³ Similar to the analysis of the cohorts of unrelated individuals, an additive genetic model was used with the adjustment for the first ten principal components, and dosage information was analyzed for genotyped and imputed SNPs in the regression model implemented in R routines.

Exclusions: Samples were excluded if they had missing gender information, genotyping success rate <95% , extreme heterozygosity rates, cryptic relationships, high number of Mendel errors in families, a high number of discordant genotypes at SNPs common to both the Affy6.0 platform and the ITMAT-BROAD-CARE (IBC) array,⁵⁴ or were contaminated samples, duplicates, outliers in the nearest neighbour and “clustering based on missingness” analyses in PLINK, and samples unlikely to be from African-Americans based on principal component analysis results. In addition, users of anti-coagulation treatment, those with extreme raw fibrinogen values (off 6SD from the mean), and genetic outliers were also excluded.

For all meta-analysis performed in this study, summary β and standard error (SE) estimates as well as P values, which were corrected for the GWA inflation coefficient computed for each cohort, were calculated for all SNPs. SNPs with low imputation quality (<0.3), low MAF (<0.01), or present in less than one third of the studies were excluded from the meta-analysis. All QC checks and meta-analyses were conducted in parallel at two sites by independent researchers. The results were later compared and differences were checked for correctness.

Expression data analyses:

Total RNA from human ASAP liver specimens was isolated using RNeasy Lysis Buffer (Ambion, Austin, Tex), Trizol (BRL-Life Technologies) and RNeasy Mini kit (Qiagen), including treatment with RNase-free DNase set (Qiagen) according to the manufacturer’s instructions. RNA quality was determined with an Agilent 2100 bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA), and quantity was measured by a NanoDrop (Thermo Scientific). Global gene expression in ASAP data was obtained for these samples using Affymetrix ST 1.0 Exon arrays and genotyping in was performed on Illumina Human 610W-Quad Beadarrays, with subsequent imputation based on the 1000 Genomes CEU reference panel. Associations between SNP genotype and gene expression level were examined using additive linear models. P values for all genotype-gene expression level combinations were included in an FDR calculation, which was conducted by using the Benjamini-Hochberg method⁵⁵, as implemented in the

multtest R-package R-2.13.0 (<http://www.bioconductor.org/packages/release/bioc/html/multtest.html>). Further details about the methods used in ASAP are described elsewhere⁵⁶.

Heritability estimation methods:

For **FHS**, heritability was estimated using a variance components model implemented in SOLAR⁵⁷ software adjusted for covariates age and sex (Sequential Oligogenic Linkage Analysis Routines).

The **SardiNIA** cohort is a family-based cohort including 6,148 individuals organized into 1,246 multiple complex pedigrees up to five generations each. Heritability was estimated using a variance components model to take into account different types of familial relatedness in estimating the correlation among individuals, and simultaneously adjust for non-genetic effects of covariates, such as age, age2 and gender as previously described³.

For **Croatia-Vis Croatia-Korcula and Orcades**, effects of covariates and variance components were estimated by maximum likelihood in a general linear mixed model.

Heritability was estimated using the polygenic function of GenABEL with sex and age as fixed effects and an additive polygenic effect and a residual effect as random effects. The pair-wise kinship coefficients were estimated from the genomic data using the gkin function of GenABEL.

For the **NTR**, heritability analyses were performed by comparing the resemblance in fibrinogen of monozygotic (MZ) and dizygotic (DZ) twins as well as between non-twin siblings and parents and offspring. A total of 7707 family members were used in the analysis.

Zygoty of the same-sex twins was determined by DNA typing for 29% of the pairs. For the other twin pairs, zygoty was based on eight items on physical similarity and the frequency of confusion of the twins by parents, other family members and strangers. Agreement between zygoty based on these items and zygoty based on DNA is 97%.

Extending the classical twin design with additional family members such as non-twin siblings and parents^{58, 59} makes it possible to simultaneously estimate the contribution of shared environmental as well as additive and dominant genetic factors to the variance in fibrinogen. Potential assortative mating is taken into account by co-modeling the spouse correlation. Structural equation modeling in Mx⁶⁰ was employed to obtain a saturated model that estimated the correlations between fibrinogen in twins, siblings and their parents. In total, 10 correlations were estimated: 1 correlation between the parents, 4 parent-offspring correlations (father-son, father-daughter, mother-son and mother-daughter) and 5 twin and sibling correlations (MZM, MZF, DZM = male sibling/male sibling = male sibling/male twin, DZF = female sibling/female sibling = female sibling/female twin, and DOS = opposite-sex sibling/opposite-sex sibling = opposite-sex sibling/opposite-sex twin) after establishing that the twin/twin and twin/sib correlations could be equated. Next the variance in fibrinogen in individuals in the parental and offspring generations was decomposed into genetic and environmental variances, while modeling the effects of phenotypic assortative mating between parents. We used the factor model described by Neale and colleagues.⁶¹ The variance decomposition was assumed to be stable across generations.

In the model that best fitted the observed variance-covariance matrices, additive genetic and shared environmental factors entirely accounted for the familial resemblance. Heritability of fibrinogen was 31%, the shared environment accounted for 10% of the variance in fibrinogen. More than half of the

variance in fibrinogen (59%) was due to environmental factors unique to each individual which also include measurement error.

The proportion of variance in plasma fibrinogen concentration accounted for by the lead SNPs and the corresponding proportion of variance explained by the effect of smoking and BMI were computed using data from 88,251 European-ancestry by regressing the natural log-transformed fibrinogen residuals, after adjustment for age and sex (and cohort specific covariates), against the lead SNPs (or the effect of smoking and BMI). The mean, median and standard deviation of r^2 values obtained in individual cohorts were reported.

Given the known positive associations of BMI and smoking with the plasma fibrinogen concentration, we also calculated the proportion of variance explained by these two covariates in our sample.

GRS methods

The GRS was computed for each individual by weighting the dosage number of fibrinogen-raising alleles by the global beta value of the allele (obtained from the European-ancestry meta-analysis). The added weighted dosage number of all lead SNPs (genotype score per individual) was then rescaled from 0 to 100 for each individual. All cohorts reported fibrinogen mean and standard deviation values for a set of pre-defined genotype score intervals. In addition, we used the genotype scores from the European-ancestry discovery analysis to examine associations with plasma fibrinogen concentration in the African-American and Hispanic cohorts, using methods described elsewhere.⁶²

Power calculations

We used a freely available power calculator (<http://pngu.mgh.harvard.edu/~purcell/gpc/>)⁶³ in order to assess the statistical power for the replications in African-American and Hispanic samples, as well as the lookups in stroke and VTE.

For the calculations of the replication sample size, we assumed an average variance explained by the 24 lead-SNPs of 0.16% (3.7%/24 SNPs). According to this, the replication sample size in African-American was estimated to have 72% power to detect a SNP explaining 0.16% of the variance in fibrinogen level, whereas the Hispanic sample was estimated to have 58% power to detect a SNP explaining this same proportion of the variance in fibrinogen level.

Assuming a prevalence of CAD of 0.073, we had 74% power to detect the effect of any SNP with MAF > 0.1 associated with an Odds Ratio of 1.05 (highest OR from our results, rs11242111) at the significance level of 0.002. The minimum OR required for 80% power in these conditions would be 1.052. In contrast, assuming a prevalence of stroke of 0.005, we had 4% power to detect the effect of any SNP using the same parameters. The minimum OR required for 80% power in these conditions would be 1.146. Finally, assuming a prevalence of VTE of 0.004, we had 4% power to detect the effect of any SNP using the same parameters. The minimum OR required for 80% power in these conditions would be 1.173.

Supplementary Results:

Heritability estimates and Proportion of Variance Explained by the SNPs.

Heritability estimation was conducted in participating family studies. Cohort-specific and overall average heritability estimates are summarized below:

CROATIA_Vis	0.15
CROATIA_Korcula	0.46
ORCADES	0.16
FHS	0.51
SardiNIA	0.25
NTR	0.31
average	0.31
SD	0.15

Consortia membership

Membership of Wellcome Trust Case Control Consortium 2

Management Committee: Peter Donnelly (Chair)^{1,2}, Ines Barroso (Deputy Chair)³, Jenefer M Blackwell^{4,5}, Elvira Bramon⁶, Matthew A Brown⁷, Juan P Casas⁸, Aiden Corvin⁹, Panos Deloukas³, Audrey Duncanson¹⁰, Janusz Jankowski¹¹, Hugh S Markus¹², Christopher G Mathew¹³, Colin NA Palmer¹⁴, Robert Plomin¹⁵, Anna Rautanen¹, Stephen J Sawcer¹⁶, Richard C Trembath¹³, Ananth C Viswanathan¹⁷, Nicholas W Wood¹⁸

Data and Analysis Group: Chris C A Spencer¹, Gavin Band¹, Céline Bellenguez¹, Colin Freeman¹, Garrett Hellenthal¹, Eleni Giannoulatou¹, Matti Pirinen¹, Richard Pearson¹, Amy Strange¹, Zhan Su¹, Damjan Vukcevic¹, Peter Donnelly^{1,2}

DNA, Genotyping, Data QC and Informatics Group: Cordelia Langford³, Sarah E Hunt³, Sarah Edkins³, Rhian Gwilliam³, Hannah Blackburn³, Suzannah J Bumpstead³, Serge Dronov³, Matthew Gillman³, Emma Gray³, Naomi Hammond³, Alagurevathi Jayakumar³, Owen T McCann³, Jennifer Liddle³, Simon C Potter³, Radhi Ravindrarajah³, Michelle Ricketts³, Matthew Waller³, Paul Weston³, Sara Widaa³, Pamela Whittaker³, Ines Barroso³, Panos Deloukas³.

Publications Committee: Christopher G Mathew (Chair)¹³, Jenefer M Blackwell^{4,5}, Matthew A Brown⁷, Aiden Corvin⁹, Chris C A Spencer¹

1 Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK; 2 Dept Statistics, University of Oxford, Oxford OX1 3TG, UK; 3 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK; 4 Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia 6008; 5 Cambridge Institute for Medical Research, University of Cambridge

School of Clinical Medicine, Cambridge CB2 0XY, UK; 6 Department of Psychosis Studies, NIHR Biomedical Research Centre for Mental Health at the Institute of Psychiatry, King's College London and The South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AF, UK; 7 University of Queensland Diamantina Institute, Brisbane, Queensland, Australia; 8 Dept Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT and Dept Epidemiology and Public Health, University College London WC1E 6BT, UK; 9 Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine, Trinity College Dublin, Dublin 2, Eire; 10 Molecular and Physiological Sciences, The Wellcome Trust, London NW1 2BE; 11 Department of Oncology, Old Road Campus, University of Oxford, Oxford OX3 7DQ, UK, Digestive Diseases Centre, Leicester Royal Infirmary, Leicester LE7 7HH, UK and Centre for Digestive Diseases, Queen Mary University of London, London E1 2AD, UK; 12 Clinical Neurosciences, St George's University of London, London SW17 0RE; 13 King's College London Dept Medical and Molecular Genetics, King's Health Partners, Guy's Hospital, London SE1 9RT, UK; 14 Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 15 King's College London Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK; 16 University of Cambridge Dept Clinical Neurosciences, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; 17 NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK; 18 Dept Molecular Neuroscience, Institute of Neurology, Queen Square, London WC1N 3BG, UK.

Membership of The CARDIOGRAM Consortium

Executive Committee: Sekar Kathiresan^{1,2,3}, Muredach P. Reilly⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}

Executive Secretary: Jeanette Erdmann^{7,79}

Steering Committee: Themistocles L. Assimes⁸, Eric Boerwinkle⁹, Jeanette Erdmann^{7,79}, Alistair Hall¹⁰, Christian Hengstenberg¹¹, Sekar Kathiresan^{1,2,3}, Inke R. König¹², Reijo Laaksonen¹³, Ruth McPherson¹⁴, Muredach P. Reilly⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}, John R. Thompson¹⁵, Unnur Thorsteinsdottir^{16,17}, Andreas Ziegler¹²

Statisticians: Inke R. König¹² (chair), John R. Thompson¹⁵ (chair), Devin Absher¹⁸, Li Chen¹⁹, L. Adrienne Cupples^{20,21}, Eran Halperin²², Mingyao Li²³, Kiran Musunuru^{1,2,3}, Michael Preuss^{12,7}, Arne Schillert¹², Gudmar Thorleifsson¹⁶, Benjamin F. Voight^{2,3,24}, George A. Wells²⁵

Writing group: Themistocles L. Assimes⁸, Panos Deloukas²⁶, Jeanette Erdmann^{7,79}, Hilma Holm¹⁶, Sekar Kathiresan^{1,2,3}, Inke R. König¹², Ruth McPherson¹⁴, Muredach P. Reilly⁴, Robert Roberts¹⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}, Alexandre F. R. Stewart¹⁴

ADVANCE: Devin Absher¹⁸, Themistocles L. Assimes⁸, Stephen Fortmann⁸, Alan Go²⁷, Mark Hlatky⁸, Carlos Iribarren²⁷, Joshua Knowles⁸, Richard Myers¹⁸, Thomas Quertermous⁸, Steven Sidney²⁷, Neil Risch²⁸, Hua Tang²⁹

CADomics: Stefan Blankenberg³⁰, Tanja Zeller³⁰, Arne Schillert¹², Philipp Wild³⁰, Andreas Ziegler¹², Renate Schnabel³⁰, Christoph Sinning³⁰, Karl Lackner³¹, Laurence Tiret³², Viviane Nicaud³², Francois Cambien³², Christoph Bickel³⁰, Hans J. Rupprecht³⁰, Claire Perret³², Carole Proust³², Thomas Münzel³⁰

CHARGE: Maja Barbalic³³, Joshua Bis³⁴, Eric Boerwinkle⁹, Ida Yii-Der Chen³⁵, L. Adrienne Cupples^{20,21}, Abbas Dehghan³⁶, Serkalem Demissie-Banjaw^{37,21}, Aaron Folsom³⁸, Nicole Glazer³⁹, Vilmundur Gudnason^{40,41}, Tamara Harris⁴², Susan Heckbert⁴³, Daniel Levy²¹, Thomas Lumley⁴⁴, Kristin Marcianti⁴⁵, Alanna Morrison⁴⁶, Christopher J. O'Donnell⁴⁷, Bruce M. Psaty⁴⁸, Kenneth Rice⁴⁹, Jerome I. Rotter³⁵, David S. Siscovick⁵⁰, Nicholas Smith⁴³, Albert Smith^{40,41}, Kent D. Taylor³⁵, Cornelia van Duijn³⁶, Kelly Volcik⁴⁶, Jacqueline Whitteman³⁶, Vasam Ramachandran⁵¹, Albert Hofman³⁶, Andre Uitterlinden^{52,36}

deCODE: Solveig Gretarsdottir¹⁶, Jeffrey R. Gulcher¹⁶, Hilma Holm¹⁶, Augustine Kong¹⁶, Kari Stefansson^{16,17}, Gudmundur Thorgeirsson^{53,17}, Karl Andersen^{53,17}, Gudmar Thorleifsson¹⁶, Unnur Thorsteinsdottir^{16,17}

GERMIFS I and II: Jeanette Erdmann^{7,79}, Marcus Fischer¹¹, Anika Grosshennig^{12,7}, Christian Hengstenberg¹¹, Inke R. König¹², Wolfgang Lieb⁵⁴, Patrick Linsel-Nitschke⁷, Michael Preuss^{12,7}, Klaus Stark¹¹, Stefan Schreiber⁵⁵, H.-Erich Wichmann^{56,58,59}, Andreas Ziegler¹², Heribert Schunkert^{7,79}

GERMIFS III (KORA): Zouhair Aherrahrou^{7,79}, Petra Bruse^{7,79}, Angela Doering⁵⁶, Jeanette Erdmann^{7,79}, Christian Hengstenberg¹¹, Thomas Illig⁵⁶, Norman Klopp⁵⁶, Inke R. König¹², Patrick Diemert⁷, Christina Loley^{12,7}, Anja Medack^{7,79}, Christina Meisinger⁵⁶, Thomas Meitinger^{57,60}, Janja Nahrstedt^{12,7}, Annette Peters⁵⁶, Michael Preuss^{12,7}, Klaus Stark¹¹, Arnika K. Wagner⁷, H.-Erich Wichmann^{56,58,59}, Christina Willenborg^{7,79}, Andreas Ziegler¹², Heribert Schunkert^{7,79}

LURIC/AtheroRemo: Bernhard O. Böhm⁶¹, Harald Dobnig⁶², Tanja B. Grammer⁶³, Eran Halperin²², Michael M. Hoffmann⁶⁴, Marcus Kleber⁶⁵, Reijo Laaksonen¹³, Winfried März^{63,66,67}, Andreas Meinitzer⁶⁶, Bernhard R. Winkelmann⁶⁸, Stefan Pilz⁶², Wilfried Renner⁶⁶, Hubert Scharnagl⁶⁶, Tatjana Stojakovic⁶⁶, Andreas Tomaschitz⁶², Karl Winkler⁶⁴

MIGen: Benjamin F. Voight^{2,3,24}, Kiran Musunuru^{1,2,3}, Candace Guiducci³, Noel Burt³, Stacey B. Gabriel³, David S. Siscovick⁵⁰, Christopher J. O'Donnell⁴⁷, Roberto Elosua⁶⁹, Leena Peltonen⁴⁹, Veikko Salomaa⁷⁰, Stephen M. Schwartz⁵⁰, Olle Melander²⁶, David Altshuler^{71,3}, Sekar Kathiresan^{1,2,3}

OHGS: Alexandre F. R. Stewart¹⁴, Li Chen¹⁹, Sonny Dandona¹⁴, George A. Wells²⁵, Olga Jarinova¹⁴, Ruth McPherson¹⁴, Robert Roberts¹⁴

PennCATH/MedStar: Muredach P. Reilly⁴, Mingyao Li²³, Liming Qu²³, Robert Wilensky⁴, William Matthai⁴, Hakon H. Hakonarson⁷², Joe Devaney⁷³, Mary Susan Burnett⁷³, Augusto D. Pichard⁷³, Kenneth M. Kent⁷³, Lowell Satler⁷³, Joseph M. Lindsay⁷³, Ron Waksman⁷³, Christopher W. Knouff⁷⁴, Dawn M. Waterworth⁷⁴, Max C. Walker⁷⁴, Vincent Mosser⁷⁴, Stephen E. Epstein⁷³, Daniel J. Rader^{75,4}

WTCCC: Nilesh J. Samani^{5,6}, John R. Thompson¹⁵, Peter S. Braund⁵, Christopher P. Nelson⁵, Benjamin J. Wright⁷⁶, Anthony J. Balmforth⁷⁷, Stephen G. Ball⁷⁸, Alistair S. Hall¹⁰, Wellcome Trust Case Control Consortium

1 Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; 2 Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA; 3 Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; 4 The Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA; 5 Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK; 6 Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK; 7 Medizinische Klinik II, Universität zu Lübeck, Lübeck, Germany; 8 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; 9 University of Texas Health Science Center, Human Genetics Center and Institute of Molecular Medicine, Houston, TX, USA; 10 Division of Cardiovascular and Neuronal Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, UK; 11 Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Regensburg, Germany; 12 Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Lübeck, Germany; 13 Science Center, Tampere University Hospital, Tampere, Finland; 14 The John & Jennifer Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Canada; 15 Department of Health Sciences, University of Leicester, Leicester, UK; 16 deCODE Genetics, 101 Reykjavik, Iceland; 17 University of Iceland, Faculty of Medicine, 101 Reykjavik, Iceland; 18 Hudson Alpha Institute, Huntsville, Alabama, USA; 19 Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada, K1Y 4W7; 20 Department of Biostatistics, Boston University School of Public Health, Boston, MA USA; 21 National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA, USA; 22 The Blavatnik School of Computer Science and the Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv, Israel, and the International Computer Science Institute, Berkeley, CA, USA; 23 Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA; 24 Department of Medicine, Harvard Medical School, Boston, MA, USA; 25 Research Methods, Univ Ottawa Heart Inst; 26 Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, Scania University Hospital, Lund University, Malmö, Sweden; 27 Division of Research, Kaiser Permanente, Oakland, CA, USA; 28 Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA; 29 Dept Cardiovascular Medicine, Cleveland Clinic; 30 Medizinische Klinik und Poliklinik, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, Mainz, Germany; 31 Institut für Klinische Chemie und Laboratoriumsmedizin, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, Mainz, Germany; 32 INSERM UMRS 937, Pierre and Marie Curie University (UPMC, Paris 6) and Medical School, Paris, France; 33 University of Texas Health Science Center, Human Genetics Center, Houston, TX, USA; 34 Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, WA USA; 35 Cedars-Sinai Medical Center, Medical Genetics Institute, Los Angeles, CA, USA; 36 Erasmus Medical Center, Department of Epidemiology, Rotterdam, The Netherlands; 37 Boston University, School of Public Health, Boston, MA, USA; 38 University of Minnesota School of Public Health, Division of Epidemiology and Community Health, School of Public Health (A.R.F.), Minneapolis, MN, USA; 39 University of Washington, Cardiovascular Health Research Unit and Department of Medicine, Seattle, WA, USA; 40 Icelandic Heart Association, Kopavogur Iceland; 41 University of Iceland, Reykjavik, Iceland; 42 Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda MD, USA; 43 University of Washington, Department of Epidemiology, Seattle, WA, USA; 44 University of Washington, Department of Biostatistics, Seattle, WA, USA; 45 University of Washington,

Department of Internal Medicine, Seattle, WA, USA; 46 University of Texas, School of Public Health, Houston, TX, USA; 47 National Heart, Lung and Blood Institute, Framingham Heart Study, Framingham, MA and Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; 48 Center for Health Studies, Group Health, Departments of Medicine, Epidemiology, and Health Services, Seattle, WA, USA; 49 The Wellcome Trust Sanger Institute, The Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; 50 Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle; 51 Boston University Medical Center, Boston, MA, USA; 52 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; 53 Department of Medicine, Landspítali University Hospital, 101 Reykjavik, Iceland; 54 Boston University School of Medicine, Framingham Heart Study, Framingham, MA, USA; 55 Institut für Klinische Molekularbiologie, Christian-Albrechts Universität, Kiel, Germany; 56 Institute of Epidemiology, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany; 57 Institut für Humangenetik, Helmholtz Zentrum München, Deutsches Forschungszentrum für Umwelt und Gesundheit, Neuherberg, Germany; 58 Institute of Medical Information Science, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Germany; 59 Klinikum Grosshadern, Munich, Germany; 60 Institut für Humangenetik, Technische Universität München, Germany; 61 Division of Endocrinology and Diabetes, Graduate School of Molecular Endocrinology and Diabetes, University of Ulm, Ulm, Germany; 62 Division of Endocrinology, Department of Medicine, Medical University of Graz, Austria; 63 Synlab Center of Laboratory Diagnostics Heidelberg, Heidelberg, Germany; 64 Division of Clinical Chemistry, Department of Medicine, Albert Ludwigs University, Freiburg, Germany; 65 LURIC non profit LLC, Freiburg, Germany; 66 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Austria; 67 Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, University of Heidelberg, Germany; 68 Cardiology Group Frankfurt-Sachsenhausen, Frankfurt, Germany; 69 Cardiovascular Epidemiology and Genetics Group, Institut Municipal d'Investigació Mèdica, Barcelona; Ciber Epidemiología y Salud Pública (CIBERSP), Spain; 70 Chronic Disease Epidemiology and Prevention Unit, Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland; 71 Department of Molecular Biology and Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, USA; 72 The Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 73 Cardiovascular Research Institute, Medstar Health Research Institute, Washington Hospital Center, Washington, DC 20010, USA; 74 Genetics Division and Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA; 75 The Institute for Translational Medicine and Therapeutics, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 76 Department of Cardiovascular Surgery, University of Leicester, Leicester, UK; 77 Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, LS2 9JT, UK; 78 LIGHT Research Institute, Faculty of Medicine and Health, University of Leeds, Leeds, UK; 79 Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Universität zu Lübeck, Lübeck, Germany.

CARDIoGRAM Disclosures: Dr Absher reports receiving an NIH research grant for the ADVANCE study. Dr Assimes reports receiving an NIH research grant for the ADVANCE study. Dr Blankenberg reports receiving research grants from NGFNplus for Atherogenomics and from BMBF for CADomics. Dr Boerwinkle received research support from NIH/National Human Genome Research Institute (NHGRI), GWA for gene-environment interaction effects influencing CGD; NIH/NHLBI, Molecular epidemiology of essential hypertension; NIH/NHLBI, Genome-wide association for loci influencing

coronary heart disease; NIH/NHLBI, Genetics of hypertension-associated treatment; NIH/NHLBI, Modeling DNA diversity in reverse cholesterol transport; NIH/NHLBI, 20-year changes in fitness and cardiovascular disease risk; NIH/NHLBI, Genetic epidemiology of sodium-lithium countertransport; NIH/National Institute of General Medical Sciences (NIGMS), Pharmacogenomic evaluation of antihypertensive responses; NIH/NIGMS, Genomic approaches to common chronic disease; NIH/NHLBI, Genes of the CYP450-derived eicosanoids in subclinical atherosclerosis; NIH/NHGRI-University of North Carolina, Chapel Hill, Genetic epidemiology of causal variants across the life course; and NIH/NHLBI, Building on GWAS for NHLBI-diseases: the CHARGE consortium. Dr Cupples reports receiving research grants from NIH/NHLBI, The Framingham Heart Study; NIH/NHLBI, Genome-wide association study of cardiac structure and function; NIH/NHLBI, Functional evaluation of GWAS loci for cardiovascular intermediate phenotypes; and NIH/NHLBI, Building on GWAS for NHLBI-diseases: the CHARGE consortium. Dr Halperin reports receiving research grants from NIH, subcontract Genome-wide association study of Non Hodgkin's lymphoma; ISF, Efficient design and analysis of disease association studies; EU, consultant AtheroRemo; NSF, Methods for sequencing based associations; BSF, Searching for causal genetic variants in breast cancer and honoraria from Scripps Institute, UCLA. Dr Halperin also reports ownership interest in Navigenics. Dr Hengstenberg reports receiving research grants for EU Cardiogenics. Dr Holm reports receiving a research grant from NIH; providing expert witness consultation for the district court of Reykjavik; serving as member of the editorial board for *decodeme*, a service provided by deCODE Genetics; and employment with deCODE Genetics. Dr Li reports receiving research grant R01HG004517 and other research support in the form of coinvestigator on several NIH-funded grants and receiving honoraria from National Cancer Institute Division of Cancer Epidemiology and Genetics. Dr McPherson reports receiving research grants from Heart & Stroke Funds Ontario, CIHR, and CFI. Dr Rader reports receiving research grant support from GlaxoSmithKline. Dr Roberts reports receiving research grants from the Cystic Fibrosis Foundation, NIH, and Cancer Immunology and Hematology Branch; membership on the speakers bureau for AstraZeneca; receiving honoraria from Several; and serving as consultant/advisory board member for Celera. Dr Stewart reports receiving research grant support from CIHR, Genome-wide scan to identify coronary artery disease genes, and CIHR, Genetic basis of salt-sensitive hypertension in humans; other research support from CFI: Infrastructure support; and honoraria from the Institute for Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Dr Thorleifsson is an employee of deCODE Genetics. Dr Thorsteinsdottir reports receiving research grants from NIH and EU; serving as an expert witness for a US trial; having stock options at deCODE Genetics; and having employment with deCODE Genetics. Dr Kathiresan reports receiving research grants from Pfizer, Discovery of type 2 diabetes genes, and Alnylam, Function of new lipid genes, and serving as consultant/advisory board member for DAIICHI SANKYO Merck. Dr Reilly reports receiving research grant support from GlaxoSmithKline. Dr Schunkert reports receiving research grants from the EU, project Cardiogenics; NGFN, project Atherogenomics; and CADnet BMBF. M. Preuss, L. Chen, and Drs König, Thompson, Erdmann, Hall, Laaksonen, März, Musunuru, Nelson, Burnett, Epstein, O'Donnell, Quertermous, Schillert, Stefansson, Voight, Wells, Ziegler, and Samani have no conflicts to disclose. Genotyping of PennCATH and MedStar was supported by GlaxoSmithKline. Dawn M. Waterworth, Max C. Walker, and Vincent Mooser are employees of GlaxoSmithKline. PennCath/MedStar investigators acknowledge the support of Eliot Ohlstein, Dan Burns and Allen Roses at GlaxoSmithKline.

Supplementary Table S1: Cohort characteristics for the participants in the meta-analysis performed in European-descent individuals.

Cohort name	Counts	Mean age, years (SD)	Male, %	BMI, kg/m ² (SD)	Arterial disease hx, %	Current smokers, %	Venous disease hx, %	T2D, %	Measurement	Assay Type	Fibrinogen Mean (SD), g/l	Ln Fibrinogen Mean (SD)
Procardis imm controls	2224	55.2 (8.3)	76.1	26.3 (3.77)	0	20.8	NA	2.3	EDTA	imm-neph	3.53 (0.83)	1.24 (0.23)
Procardis imm cases	1168	63.6 (6.9)	68.4	28.7 (4.65)	100	56.3	NA	14.6	EDTA	imm-neph	4.48 (1.00)	1.48 (0.22)
Procardis Clauss	3489	61.9 (7.4)	75.5	28.3 (4.87)	100	50.3	NA	15.2	Citrate	Clauss	3.85 (0.86)	1.32 (0.22)
FHS	7022	46.6 (11.5)	46.1	27.0 (5.20)	10.8	18.9	NA	4.8	Citrate	Clauss	3.2 (0.7)	1.2 (0.2)
WGHS	23080	54.7 (7.1)	0	25.9 (5.00)	0	0.1	0.03	0.03	Citrate/EDTA	imm--turb	3.59 (0.78)	1.26 (0.21)
SardiNIA	4691	43.3 (17.6)	43.7	25.3 (4.68)	3.3	19.8	NA	2.2	Citrate	Clauss	3.28 (0.66)	1.19 (0.2)
RS	2068	70.8 (9.0)	36.8	26.5 (3.90)	7.9	22.2	NA	11.8	Citrate	Funtional*	2.81 (0.69)	1.03 (0.2)
SHIP	3841	48.8 (16.1)	48.5	27.2 (4.76)	NA	31.4	NA	8.2	Citrate	Clauss	2.99 (0.70)	1.07 (0.22)
CARDIA	1435	25.6 (3.3)	47	25.4 (5.09)	10.8	20.3	NA	1.1	Citrate/EDTA	imm-neph	3.18 (0.66)	1.14 (0.20)
PROSPER/PHASE	5244	75.3 (3.4)	47	26.8 (4.20)	45	27	0	10	EDTA	Clauss	3.60 (0.74)	1.26 (0.21)
CHS	3227	72.3 (5.4)	39	26.3 (4.42)	0	11.4	4.34	14	Citrate	Clauss	3.15 (0.62)	1.13 (0.19)
LBC1936	989	69.6 (0.8)	50.8	27.8 (4.42)	28.4*	12.6	NA	7.7	Citrate	Clauss	3.27 (0.63)	1.17 (0.19)
LBC1921	486	79.1 (0.6)	42.6	26.2 (4.11)	34.5 *	6.6	NA	4.9	Citrate	Clauss	3.59 (0.86)	1.25 (0.24)
MARTHA08	613	44.1 (14.2)	23.8	24.3 (4.41)	<1	25.9	100	NA	Citrate	Clauss	3.36 (0.68)	1.19 (0.2)
MARTHA10	374	47.3 (15.8)	36	25.7 (4.78)	<1	24.2	100	NA	Citrate	Clauss	3.41 (0.74)	1.21 (0.21)
CROATIA-Split	492	49.1 (14.6)	42.5	26.9 (4.18)	NA	24.8	NA	4.9	Citrate	Clauss	3.84 (1.17)	1.30 (0.30)
CROATIA-Korcula	801	56.3 (15.6)	35.3	28.0 (4.14)	NA	25.3	NA	8.4	Citrate	Clauss	4.56 (1.51)	1.47 (0.33)
CROATIA-Vis	882	56.3 (15.6)	42.7	27.4 (4.28)	NA	24	NA	5.7	Citrate	Clauss	3.57 (0.80)	1.25 (0.22)
ORCADES	882	53.6 (15.8)	45.2	27.7 (4.84)	NA	6.8	NA	3.4	Citrate	Clauss	3.48 (0.86)	1.22 (0.23)
B58C	6085	45.2 (0.4)	49.7	27.4 (4.85)	NA	23.5	NA	1.5	Citrate	Clauss	2.95 (0.60)	1.06 (0.20)
KORA F3	1523	52.1 (10.2)	49.3	27.2 (4.10)	0.7	18.1	NA	3.7	EDTA	imm-neph	2.89 (0.66)	1.03 (0.22)
KORA F4	1788	53.9 (8.9)	48.9	27.7 (4.50)	2.1	20.1	NA	3.5	EDTA	imm-neph	2.67 (0.60)	0.96 (0.22)
InCHIANTI	1196	68.4 (15.4)	44.4	27.2 (4.14)	15.5	18.8	NA	11.2	Citrate	Clauss	3.51 (0.77)	1.23 (0.22)
Twins UK	2049	49.3 (12.4)	4.7	25.6 (4.53)	1.1	NA	NA	NA	Citrate	Clauss	2.99 (0.78)	1.06 (0.24)
HBCS	1401	61.4 (2.9)	40.2	27.4 (4.50)	NA	23.9	NA	11.7	EDTA	Clauss	3.23 (1.04)	1.12 (0.34)
NTR	2490	48.0 (14.0)	37.6	25.5 (4.02)	2.4	20.3	6.3	3.8	Citrate	Clauss	2.79 (0.66)	1.00(0.25)
ARIC EA	9256	54.3 (5.7)	47.1	27.0 (4.80)	6.35	24.6	2.01	8.6	Citrate	Clauss	2.97 (0.61)	1.07 (0.20)
MESA	2527	62.7 (10.2)	47.7	27.7 (5.07)	NA	11.4	NA	6.0	Citrate	imm-neph	3.35 (0.70)	1.19 (0.21)

Imm-neph= immunonephelometric; imm-turb= immunoturbidimetric; *Functional PT-derived method (Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res. 1988;52:453-68).

Supplementary Table S2: Cohort characteristics for the participants in the meta-analysis performed in individuals of African-American- or Hispanic descent.

Cohort name	Counts	Mean age, years (SD)	Male, %	Ancestry	BMI, kg/m ² (SD)	Arterial disease, %	Current smokers, %	Venous disease, %	T2D, %	Measur.	Assay Type	Fibrinogen Mean (SD), g/l	Ln Fibrinogen Mean (SD)
ARIC	2609	53.2 (5.8)	36.8	African American	29.6 (6.0)	5.8	30.1	3.1	17.9	Citrate	Clauss	3.19 (0.72)	1.14 (0.22)
MESA	1677	62.2 (10.1)	46.0	African American	30.1 (5.9)	NA	18.3	NA	17.1	Citrate	Imm-neph	3.60 (0.79)	1.25 (0.22)
MESA	1447	61.4 (10.3)	48.4	Hispanic	29.5 (5.1)	NA	13.4	NA	17.8	Citrate	Imm-neph	3.59 (0.75)	1.26 (0.20)
GeneSTAR	1144	44.5 (11.5)	38	African American	31.6 (7.6)	6.5	32	0	14	Citrate	Clauss	3.99 (1.3)	1.34 (0.31)
WHI-SHARe	1087	62.3 (7.2)	0	African American	31.5 (6.3)	6.4	11.3	2.7	16	Citrate	Clauss	3.25 (0.70)	1.18 (0.22)
CARDIA	809	24.5 (3.8)	38.2	African American	25.5 (5.7)	NA	29.2	NA	0.7	EDTA	Imm-neph	3.42(0.80)	1.20 (0.23)
CHS	784	72.8 (5.5)	37.0	African American	28.5 (5.5)	18.2	16.0	5.4	24.6	Citrate	Clauss	3.44 (0.75)	1.21 (0.21)
CFS	313	41.4 (18.5)	40.3	African American	33.3 (9.9)	NA	31	NA	24	Plasma	Clauss	3.23 (0.82)	1.13 (0.27)

Imm-neph= immunonephelometric; Measur.= measurement; T2D=Type II Diabetes

Supplementary Table S3: Genotyping details for the participants in the meta-analysis performed in European-descent individuals.

	Platform	Chip	SNPs gen	Call rate	SNP exclusion criteria*			Variants included for imputation	Percent of variants included	Imputation software	Imputation software version	Genome build	Total # of SNPs
					MAF	HWE p-value							
PROCARDIS	ILLUMINA	1M,Human610-Quad	573,015 (1M) 582,892 (610)	<0.95	<0.01	<1 x 10 ⁻⁶	498,717 (1M) 514,950 (610)	0.87 (1M) 0.88 (610)	MACH	1.0.16	36	2,543,888	
FHS	AFFYMETRIX	500K + 50K	490,700 (500K) 48,195 (50K)	≤0.97		<1 x 10 ⁻⁶	343,361 (500K) 34,841 (50K)	0.70 (500k) 0.72 (50K)	MACH	1.0.15	36.2	2,543,887	
WGHS	ILLUMINA	HumanHap300 Duo “+”	339,596	<0.90	<0.01	<1 x 10 ⁻⁶	328,963 7,134 (10K)	0.97	MACH	1.0.16	36	2,608,508	
SARDINIA	AFFYMETRIX	10K+500K+1000K	9,941 (10K) 490,033 (500K) 893,634 (1000K)	<90% (10K/500K) and <95% (6.0)	<0.05 (10K and 500K) <0.01 (1000K)	<1 x 10 ⁻³ (10K) and p <1 x 10 ⁻⁶ (500K and 1000K)	339,003 (500K) 727,541 (1000K) Combined: 731,209	0.72 (10K) 0.69 (500K) 0.81 (1000K)	MACH	1.0.10	36.3	2,325,980	
RS	ILLUMINA	ILLUMINA Infinium II HumanHap550	530,683	<0.95	≤0.01	<1.0x10 ⁻⁵	491,875	0.93	MACH	1.0.15	36	2,586,725	
SHIP	AFFYMETRIX	1000K	869,224				869,224	1	IMPUTE	0.5.0	36	2,748,910	
CARDIA	AFFYMETRIX	1000K	909,622	<0.95	≤0.02	<1.0x10 ⁻⁴	578,568	0.64	BEAGLE	3.2	36	2,276,435	
PROSPER/PHASE	ILLUMINA	Human660W-Quad	561,490	<0.97	no	<1 x 10 ⁻⁶	557,192	0.99	MACH	1.0.15	36.2	2,543,887	
CHS - EA	ILLUMINA	370 CNV	306,655	≤0.97		<1.0x10 ⁻⁵	291,322	0.95	BIMBAM	0.99	36	2,543,887	
LBC1936	ILLUMINA	Human610-Quad	542,050	<0.95	<0.01	<0.001	535,709	0.99	MACH	1.0.16	36	2,543,887	
LBC1921	ILLUMINA	Human610-Quad	542,050	<0.95	<0.01	<0.001	535,709	0.99	MACH	1.0.16	36	2,543,887	
MARTHA08	ILLUMINA	Human610-Quad	567,589	<0.99	<0.01	<1 x 10 ⁻⁵	494,721	0.87	MACH	1.0.16	35	2,557,252	
MARTHA10	ILLUMINA	Human660W-Quad	556,776	<0.99	<0.01	<1 x 10 ⁻⁵	501,773	0.90	MACH	1.0.16	35	2,557,252	
CROATIA-Split	ILLUMINA	HumanHap 370CNV-Quad	351,514	≤0.98	≤ 0.01	<1 x 10 ⁻⁶	321,456		MACH	1.0.16	36	2,543,887	
CROATIA-Korcula	ILLUMINA	HumanHap 370CNV-duo/Quad	346,034	<0.98	<0.01	<1 x 10 ⁻⁶	307,625		MACH	1.0.16	36	2,543,887	
CROATIA-Vis	ILLUMINA	HumanHap 300v1	317,509	≤0.98	≤0.01	<1 x 10 ⁻⁶	289,827		MACH	1.0.16	36	2,543,887	
ORCADES	ILLUMINA	HumanHap 300v2	351,454	<0.98	<0.01	<1 x 10 ⁻⁶	285,491		MACH	1.0.16	36	2,543,887	
B58C	ILLUMINA	550K or Human610-Quad	532,203	<0.95	<0.01	<0.0001	482,570	0.93	MACH	1.0.16	35	2,557,252	
KORA F3	AFFYMETRIX	500K	490,032	no	no	no	490,032	1	MACH	1.0.9	35;21	2,557,252	
KORA F4	AFFYMETRIX	1000K	906,716	< 0.93	no	no	651,596	0.72	MACH	1.0.15	36;22	2,543,887	
InCHIANTI	ILLUMINA	550K	549,892	<0.99	≤0.01	<1 x 10 ⁻⁶	495,343	0.90	MACH	1.0.16	36	2,543,887	
TwinsUK	ILLUMINA	HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M	NA	≤0.97, ≤0.99 (0.01<MAF<0.05)	≤0.01	<1 x 10 ⁻⁶	874,733	NA	IMPUTE	2	36	2,657,660	

HBCS	Illumina	modified 610k	509,947	none	none	none	---	---	MACH	---	36	2,544,887
NTR	Perlegen, Affymetrix, Illumina	660K (PA), 660K(I1), 370K (I2)	599,156 (PA) 657,366 (I1) 370,404 (I2)	<0.95	≤0.01	<0.00001	427,099 (PA) 528,027 (I1) 318,237 (I2)	71% (PA) 80%(I1) 85%(I2)	IMPUTE	1	36	2,538,588
ARIC EA	Affymetrix	1000K	841,820	<0.95	≤0.01	<1.0x10 ⁻⁵	669,450	0.795	MACH	1.0.16	36	2,543,887
MESA	Affymetrix	1000K	854,756	<0.95	≤0.01	<1.0x10 ⁻⁶	854,756	0.85	IMPUTE	2.1.0	36	2,545,579

SNPs gen= single nucleotide polymorphisms genotyped.

Supplementary Table S4: Genotyping details for the participants in the meta-analysis performed in African American and Hispanic-descent individuals.

Cohort	Genotyping Details			SNP exclusion criteria*			Imputation Details			Total # of SNPs		
	Platform	Chip	SNPs gen	Call rate	MAF	HWE p-value	Variants included for imputation	Percent of variants included	Imputation software		Imputation software version	Genome build
ARIC AA	Affymetrix	1000K	909,622	<0.95	<0.01	None†	Not available‡	Not available‡	MACH	1.0.16	36	2,796,485
MESA	Affymetrix	1000K	841,820	<0.95	<0.01	<1e-6	854,756	0.85	IMPUTE	2.1.0	36	~2.5M
GeneSTAR	Illumina	1Mv1_C	1,043,165	<0.90		<1e-8	687,132	0.659	MACH	1.0.16	36	2,507,621
WHI	Affymetrix	1000K	871,309	≤0.97			854,981	70% (500k) 72% (50K)	MACH	1.0.16	36.2	2,426,484
CARDIA	Affymetrix	1000K	909,622	<0.95	<0.01	None†	Not available‡	Not available‡	MACH	1.0.16	36	2,807,954
CHS – AA	Illumina	HumanOmni1-Quad_v1	1,140,419	≤0.97		<1.0x10 ⁻⁵	963,248	0.95	BEAGLE	3,2.1	36	2,770,583
CFS AA	Affymetrix	1000K	909,622	<0.95	>0.01	None†	Not available‡	Not available‡	MACH	1.0.16	36	2,547,353

†Hwe: The Hardy-Weinberg equilibrium (HWE) test was performed for all SNPs, but SNPs were not excluded based uniquely on this criterion given the admixed nature of the African American cohorts genotyped; ‡Not provided by CARE.

Supplementary Table S5. Candidate genes at newly discovered susceptibility loci for fibrinogen levels.

The table lists genes of interest in the novel associated regions. For each associated region, the reported gene either contains the lead SNP or is in closest physical proximity with the lead SNP.

SNP	Location	Gene	Function
rs789678	10q21.3	<i>JMJD1C</i>	<i>Jumonji domain containing 1C</i> encodes thyroid-hormone-receptor interactor 8, a hormone-dependent transcription factor that regulates expression of a variety of specific target genes ⁶⁴ . This locus has been found associated with levels of the liver enzyme alkaline phosphatase (ALP) and plasma lipid concentration ⁶⁵⁻⁶⁷ . In addition, it is also associated with mean platelet volume and epinephrine-induced platelet aggregation ^{68, 69} . The associated SNP is in intron 2 of the gene.
rs1938492	1p31	<i>LEPR</i>	Encodes the leptin receptor, an adipocyte-specific hormone that regulates body weight, and is involved in the regulation of fat metabolism, as well as in a novel hematopoietic pathway that is required for normal lymphopoiesis. Mutations in this gene have been associated with obesity and pituitary dysfunction. This locus has been associated with levels of the acute-phase proteins C-reactive protein (CRP) and serum amyloid A (A-SAA) ^{70, 71} . Recently, genetic variability at the <i>LEPR</i> locus has been shown to influence also plasma levels of fibrinogen ⁷² . The associated SNP maps in an intergenic region about 14 kb upstream of <i>LEPR</i> , which is the closest gene.
rs4817986	21q22.2	<i>PSMG1</i>	Encodes the proteasome assembly chaperone 1, involved in the maturation of mammalian 20S proteasomes ⁷³ . This locus is found associated with two closely related inflammatory conditions, inflammatory bowel disease (IBD) ⁷⁴ , and, although not conclusively, with ankylosing spondylitis ⁷⁵ . In addition, this locus is also found associated with levels of the acute-phase protein CRP ⁷⁰ . The associated SNP maps about 82 kb downstream of the gene, which is the closest gene in the region.
rs7204230	16q12.2	<i>CHD9</i>	Encodes the chromatin-related mesenchymal modulator (CREMM), a member of the third subfamily of chromodomain helicase DNA-binding proteins (CHD) which play a role in chromatin remodeling ⁷⁶ . It is expressed by osteoprogenitors, where it mediates the transcriptional response to hormones that coordinate osteoblast function. Furthermore, it binds to nuclear receptors such as PPARalpha, CAR, ERalpha, and RXR and with transcription cofactors CBP, PRIP, and PBP. In particular, CHD9 acts as a transcription coactivator by stimulating PPARalpha-mediated transcription, which is in turn involved in proliferation of peroxisomes in liver, induction of PPARalpha target genes including those involved in fatty acid oxidation, and the eventual development of liver tumors ⁷⁷ . The associated SNP is in intron 2 of the gene.
rs10226084	7p21.1	<i>SNX13</i>	Encodes a PHOX domain- and RGS domain-containing protein that belongs to the sorting nexin (SNX) family and the regulator of G protein signaling (RGS) family ⁷⁸ . The PHOX domain is a phosphoinositide binding domain, and the SNX family members are involved in intracellular trafficking. The RGS family members are regulatory molecules that act as GTPase activating proteins for G alpha subunits of heterotrimeric G proteins. Overexpression of this protein delays lysosomal degradation of the epidermal growth factor receptor. Because of its bifunctional role, this protein may link heterotrimeric G protein signaling and vesicular trafficking. The associated SNP maps about 17 kb upstream of <i>SNX13</i> , which is the closest gene in the region.
rs12915708	15q21.2	<i>SPPL2A</i>	This gene is a member of the signal peptide peptidase-like protease (SPPL) family and encodes an endosomal membrane protein with a protease associated (PA) domain, which plays a role in innate and adaptive immunity. SPPL2A together with SPPL2B catalyses intramembrane cleavage of tumour necrosis factor alpha (TNFalpha), which in turn triggers expression of the pro-inflammatory cytokine interleukin-12 by activated human dendritic cells ⁷⁹ . Furthermore, SPPL2A with ADAM10 is implicated in FasL processing and release of the FasL ICD, which has been shown to be important for retrograde FasL signaling ⁸⁰ . The associated SNP is in intron 2 of the gene.
rs7464572	8q24	<i>PLEC1</i>	Plectin is a member of a family of structurally and in part functionally related proteins, termed plakins, that are capable of interlinking different elements of the cytoskeleton. Plakins play crucial roles in maintaining cell and tissue integrity and orchestrating dynamic changes in cytoarchitecture and cell shape, but also serve as scaffolding platforms for the assembly, positioning, and regulation of signaling

			complexes. It has been shown that, via effects on cytoskeletal organization, plectin deficiency might play an important role in the transformation of human liver cells ⁸¹ . In addition, RNA interference-mediated inhibition PLEC1 reduced IL-6 production by macrophages stimulated with LPS, suggesting a role for this gene in innate immunity ⁸² . Recently, this gene has been associated with HDL and total cholesterol levels ⁸³ . The associated SNP is in intron 2 of the gene.
rs1476698	2q37.3	<i>FARP2</i>	Encodes a Dbl family guanine nucleotide exchange factor (GEF) specific for Rac1. GEFs from the Dbl family integrate extracellular signaling with appropriate activation of Rho GTPases in specific subcellular regions. FARP2 plays a key role in the regulation of Rac1 and integrin β 3 throughout podosome rearrangement in osteoclastogenesis ⁸⁴ . Furthermore, it is a risk locus for chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL), a condition predisposing to CLL ^{85, 86} . It is also a candidate gene for the high-density lipoprotein (HDL) cholesterol locus on mouse chromosome 1 and is associated with HDL cholesterol in humans ^{87, 88} . The associated SNP is in intron 1 of the gene.
rs1019670	11q12.1	<i>MS4A6A</i>	Encodes a member of the membrane-spanning 4A (MS4A) gene family, which display unique expression patterns among hematopoietic cells and nonlymphoid tissues. The genes in the <i>MS4A</i> cluster on chromosome 11 are characterized by similar intron/exon splice boundaries and common structural features, including transmembrane domains indicating that they are likely to be part of a family of cell surface proteins. MS46A has no known specific function and has been identified as a susceptibility locus for Alzheimer's disease ⁸⁹ . Furthermore, it is associated with levels of the coagulation factor VII, supporting a role in the regulation of fibrinogen ^{90, 91} . The associated SNP is in exon 6 of the gene and causes a non-synonymous aminoacid change (Thr/Ser) at position 185 of the protein.
rs2286503	7p15.3	<i>TOMM7/IL6</i>	Encodes a small regulatory component of the translocase of the outer mitochondrial membrane (TOM), a general import pore complex that translocates preproteins into mitochondria. TOMM7 is a risk locus for type 2 diabetes in Mexican-Americans, although there is little literature suggesting roles for TOMM7 in diabetes ⁹² . In HapMap Europeans, LD extends from this region to include the susceptibility gene for type 2 diabetes <i>IL-6</i> . Interestingly, the pro-inflammatory cytokine IL-6 upregulates expression of tissue factor, a central player in the initiation of coagulation, supporting a role also in fibrinogen levels ⁹³ . Furthermore, IL-6 is associated with CRP levels. Although the associated SNP maps in intron 3 of <i>TOMM7</i> , the best candidate in the region appears the <i>IL-6</i> gene, located about 85 kb upstream.
rs434943	14q22-q24	<i>ACTN1</i>	Encodes alpha (α) actinin, a ubiquitous cytoskeletal protein that belongs to the superfamily of filamentous actin (F-actin) crosslinking proteins, with multiple roles in different cell types. Four isoforms of α -actinin have been identified namely, the "muscles" α -actinin-2 and α -actinin-3 and the "non-muscles" α -actinin-1 and α -actinin-4, which are generally believed to represent key structural components of large-scale F-actin cohesion in cells required for cell shape and motility. The role of non-muscles α -actinin in the liver is unknown, however α -actinin is expressed on the membrane and cytosol of cells of the liver and it seems that it interacts with hepatitis C virus and is essential for the replication of the virus, suggesting that α -actinin might play a role in the pathogenesis of liver diseases. In addition, α -actinin is as a target autoantigen in the pathogenesis of autoimmune diseases, particularly systemic lupus erythematosus and autoimmune hepatitis ⁹⁴ . A role in the immune response is also supported by the co-localization of ACTN1 (A-1) with actin and SPA-1 at the immunological synapse in T cells ⁹⁵ . Interestingly, tyrosine phosphorylation of non-muscle α -actinin is induced by platelet activation, which is associated with a decrease in the affinity of α -actinin for actin ⁹⁶ . This could in turn affect the mechanical properties of the actin cytoskeleton and induce platelet spreading. The associated SNP maps in an intergenic region about 27 kb downstream of <i>ACTN1</i> , which is the closest gene.
rs16844401	4p16	<i>HGFAC</i>	Encodes the hepatocyte growth factor activator (HGF activator), a serine protease which converts single-chain HGF to the active two-chain form. HGF activator is first synthesized as an inactive single-chain precursor, homologous to blood coagulation factor XII, that is activated to a heterodimeric form by endoproteolytic processing by thrombin. Thrombin-activated HGF activator then converts single-chain HGF, which is homologous to the fibrinolysis factor plasminogen, to the active two chain form that functions as a growth factor for

			parenchymal liver cells and may be involved in repairing the injured liver ⁹⁷ . The associated SNP maps in exon 12 of <i>HGFAC</i> .
rs12712127	2q12	<i>IL1R1</i>	Encodes a cytokine receptor for interleukin alpha (IL1A), interleukin beta (IL1B), and the interleukin 1 receptor antagonist (IL1RA). This gene along with <i>IL1R2</i> , <i>IL1RL2</i> , and <i>IL1RL1</i> form a cytokine receptor gene cluster in chromosome 2q12. <i>IL1R1</i> , together with <i>IL-1R2</i> , the antagonist <i>IL-1RA</i> , and the accessory protein <i>IL-1R AcP</i> , is an important mediator of IL1 signaling and is involved in many cytokine induced immune and inflammatory responses, including coagulation and fibrinolysis, with an overall prothrombotic effect. However, previous investigation of common variations in <i>IL1R1</i> was not associated with increased risk of venous thrombosis ⁹⁸ . <i>IL1RL1</i> polymorphisms are associated with serum <i>IL1RL1</i> -a, blood eosinophils, asthma and myocardial infarction ^{99, 100} . The associated SNP maps in an intergenic region of the chromosome 2q12 receptor cluster, about 44 kb downstream of <i>IL1R1</i> , which is the closest gene.
rs7968440	12q13.12	<i>DIP2B</i>	Encodes a member of the disco-interacting protein homolog 2 protein family. The protein contains a binding site for the transcriptional regulator DNA methyltransferase 1 associated protein 1 as well as AMP-binding sites, suggesting that it may participate in DNA methylation. <i>DIP2B</i> is located near a folate-sensitive fragile site, <i>FRA12A</i> , linked to mental retardation and individuals with the fragile site show a CGG-repeat expansion in its promoter, which affects <i>DIP2B</i> transcription ^{101, 102} . Common variants in <i>DIP2B</i> also influence risk of developing colorectal cancer. The associated SNP is located in intron 36 of the gene.
rs6010044	22q13.3	<i>SHANK3</i>	This gene is a member of the Shank gene family, which encodes multidomain scaffold proteins of the postsynaptic density that connect neurotransmitter receptors, ion channels, and other membrane proteins to the actin cytoskeleton and G-protein-coupled signaling pathways. Shank proteins also play a role in synapse formation and dendritic spine maturation. Mutations in this gene are a cause of autism spectrum disorder and of the neurological symptoms of 22q13.3 deletion syndrome ^{103, 104} . Furthermore, Shank3 is present in both EPEC- and <i>S. typhimurium</i> -induced actin rearrangements and is required for optimal EPEC pedestal formation, suggesting that this molecule is a host synaptic proteins likely to play key roles in bacteria-host interactions ¹⁰⁵ . The associated SNP maps in an intergenic region about 11 kb downstream of <i>SHANK3</i> , which is the closest gene. Gene-set enrichment analysis using MAGENTA prioritized as most plausible candidate in this region the <i>CPT1B</i> gene (see below).
rs6010044	22q13.33	<i>CPT1B</i>	Encodes a member of the carnitine/choline acetyltransferase family, which is the rate-controlling enzyme of the long-chain fatty acid beta-oxidation pathway in muscle mitochondria. This enzyme is required for the net transport of long-chain fatty acyl-CoAs from the cytoplasm into the mitochondria. Multiple transcript variants encoding different isoforms have been found for this gene, and read-through transcripts are expressed from the upstream locus that include exons from this gene. Common nonsynonymous coding variants in <i>CPT1B</i> have been associated with ectopic skeletal muscle fat among middle-aged and older African ancestry men ¹⁰⁶ . This gene takes part in adipocytokine signaling and is located about 90 kb downstream of the associated SNP.

Supplementary Table S6: Validation *P*-values in African-American and Hispanic cohorts for the 24 lead SNPs.

SNP	Band	Position	Closest gene	A		European				African-American				Hispanic			
				1	2	Freq	Beta	SE	<i>P</i>	Freq	Beta	SE	<i>P</i>	Freq	Beta	SE	<i>P</i>
rs1938492*	1p31.3	65890417	<i>LEPR</i>	A	C	0.62	0.008	0.001	5.28X10 ⁻¹⁴	0.55	0.003	0.004	0.37	0.54	-0.009	0.007	0.19
rs4129267	1q21.3	152692888	<i>IL6R</i>	T	C	0.39	-0.011	0.001	5.97X10 ⁻²⁷	0.14	-0.011	0.006	0.04	0.47	-0.031	0.007	2.10X10 ⁻⁰⁵
rs10157379	1q44	245672222	<i>NLRP3</i>	T	C	0.62	0.01	0.001	1.15X10 ⁻¹⁹	0.60	0.003	0.004	0.52	0.59	0.007	0.007	0.34
rs12712127	2q11.2	102093093	<i>IL1R1/IL1R2</i>	A	G	0.41	0.006	0.001	2.72X10 ⁻⁰⁸	0.30	0.002	0.004	0.56	0.35	0.000	0.008	1.00
rs6734238	2q13	113557501	<i>IL1F10/IL1RN</i>	A	G	0.58	-0.009	0.001	5.77X10 ⁻¹⁹	0.56	-0.012	0.004	1.94X10 ⁻⁰³	0.66	-0.011	0.008	0.17
rs715	2q34	211251300	<i>CPS1</i>	T	C	0.68	0.009	0.001	1.98X10 ⁻¹¹	0.80	0.007	0.005	0.16	0.74	0.007	0.009	0.40
rs1476698	2q37.3	241945122	<i>FARP2</i>	A	G	0.65	0.007	0.001	2.24X10 ⁻⁰⁹	0.62	0.006	0.004	0.13	0.47	0.013	0.007	0.07
rs1154988	3q22.3	137407881	<i>MSL2/PCCB</i>	A	T	0.78	-0.01	0.001	9.64X10 ⁻¹⁷	0.70	-0.001	0.004	0.76	0.78	-0.018	0.009	0.04
rs16844401	4p16.2	3419450	<i>HGFAC/LRPAP1</i>	A	G	0.08	0.015	0.003	1.74X10 ⁻⁰⁸	0.03	0.015	0.013	0.23	0.1	0.017	0.017	0.32
rs1800789	4q32.1	155702193	<i>FGF</i>	A	G	0.21	0.031	0.001	1.68X10 ⁻¹²⁷	0.10	0.032	0.006	4.02X10 ⁻⁰⁷	0.15	0.052	0.011	6.89X10 ⁻⁰⁷
rs11242111	5q31.1	131783957	<i>C5orf56/IRF1</i>	A	G	0.05	0.023	0.002	1.60X10 ⁻²¹	0.37	-0.003	0.004	0.44	0.09	-0.001	0.012	0.92
rs2106854	5q31.1	131797073	<i>C5orf56/IRF1</i>	T	C	0.21	-0.019	0.001	1.72X10 ⁻⁴⁸	0.24	-0.009	0.004	0.04	0.21	-0.024	0.009	7.00X10 ⁻⁰³
rs10226084	7p21.1	17964137	<i>SNX13/PRPS1L1</i>	T	C	0.52	-0.007	0.001	5.05X10 ⁻¹⁰	0.61	-0.004	0.004	0.36	0.49	-0.003	0.007	0.63
rs2286503	7p15.3	22823131	<i>TOMM7</i>	T	C	0.36	-0.006	0.001	6.88X10 ⁻⁰⁹	0.67	0.000	0.004	0.95	0.48	-0.002	0.007	0.76
rs7464572	8q24.3	145093155	<i>PLEC1</i>	C	G	0.6	-0.007	0.001	1.33X10 ⁻⁰⁹	0.88	-0.002	0.007	0.74	0.72	-0.015	0.008	0.06
rs7896783	10q21.3	64832159	<i>JMJD1C</i>	A	G	0.48	-0.01	0.001	8.90X10 ⁻²²	0.32	-0.010	0.004	0.01	0.31	-0.009	0.008	0.25
rs1019670	11q12.1	59697175	<i>MS4A6A</i>	A	T	0.36	-0.007	0.001	4.37X10 ⁻⁰⁹	0.10	-0.016	0.008	0.03	0.22	0.004	0.009	0.63
rs7968440	12q13.13	49421008	<i>DIP2B</i>	A	G	0.64	0.006	0.001	2.74X10 ⁻⁰⁸	0.82	0.000	0.005	0.99	0.78	0.011	0.009	0.22
rs434943	14q24.1	68383812	<i>ACTN1</i>	A	G	0.31	0.007	0.001	1.08X10 ⁻⁰⁸	0.15	-0.009	0.006	0.14	0.28	0.013	0.009	0.17
rs12915708	15q21.2	48835894	<i>SPPL2A</i>	C	G	0.3	-0.007	0.001	6.87X10 ⁻¹⁰	0.10	-0.001	0.006	0.93	0.22	-0.013	0.009	0.15
rs7204230	16q12.2	51749832	<i>CHD9</i>	T	C	0.7	0.008	0.001	1.18X10 ⁻¹⁰	0.67	0.012	0.004	3.13X10 ⁻⁰³	0.79	0.037	0.009	5.38X10 ⁻⁰⁵
rs10512597	17q25.1	70211428	<i>CD300LF</i>	T	C	0.18	-0.008	0.001	9.92X10 ⁻⁰⁹	0.64	-0.006	0.004	0.19	0.44	-0.007	0.008	0.35
rs4817986	21q22.2	39387382	<i>PSMG1</i>	T	G	0.28	-0.008	0.001	2.46X10 ⁻¹¹	0.11	-0.004	0.008	0.58	0.24	-0.025	0.010	0.01
rs6010044	22q13.33	49448804	<i>SHANK3/ARSA</i>	A	C	0.8	-0.008	0.001	3.41X10 ⁻⁰⁸	0.88	0.009	0.006	0.13	0.26	0.011	0.009	0.22

European N=91,323 individuals; African-American N=8,423 individuals, Hispanic N=1,447 individuals.

*The perfect proxy rs10789192 was used in African American and Hispanics.
 Freq=frequency; SE= standard error

Supplementary Table S7: Position and association values of the 24 lead-SNPs in the European, African-American and Hispanic cohorts. Columns R to X and AD to AK show the values for the best associated SNP in African-American (a) and Hispanic (b) cohorts located within 200Kb of the “lead SNP” found in the European cohorts (the “proxy” SNPs). Columns AL to AN show the number of independent SNPs located within the 200Kb region based on the CEU and Yourba HapMaps and the corresponding adjusted p-value threshold of significance after correcting for multiple testing. Columns AO to AR show the LD values between the “lead-SNPs” and the “proxy-SNPs”. To set the significance threshold in this exploration effort, we applied Bonferroni correction and adjusted for independent SNPs in each region (pair-wise linkage disequilibrium (LD) measure, r^2 , values below 0.5).

a)

SNP	24 LEAD SNPs in EA									24 LEAD SNPs in AA				24 "Proxy" SNPs in AA					LD between "LEAD" and "Proxy" SNPs		
	CHR	POS	GENE	A		Freq	beta	P-value	Freq	beta	P-value	best SNP for	POS	A		beta in	P-value	Distance	LD based on		
				1	2									A1	AA				1	2	in AA
AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM	AN	AO	AP	AQ	AR	AS	AT	AV	AW	AX	AY	AZ
rs1938492	1	65890417	PDE4B	a	c	0.62	0.008	5.28E-14				rs1536467	65760750	a	g	0.96	0.102	0.007	129,667	na	na
rs4129267	1	152692888	IL6R	t	c	0.39	-0.011	5.97E-27	0.14	-0.011	0.040	rs1194592	152591008	c	g	0.82	-0.016	0.001	101,880	0.011	0.015
rs10157379	1	245672222	NLRP3	t	c	0.62	0.010	1.15E-19	0.60	0.003	0.516	rs11801091	245474761	t	c	0.93	0.027	0.002	197,461	1.000	0.020
rs12712127	2	102093093	IL1R1	a	g	0.41	0.006	2.72E-08	0.3	0.002	0.556	rs17026606	102081970	a	g	0.02	-0.048	0.005	11,123	1.000	0.004
rs6734238	2	113557501	IL1RN	a	g	0.58	-0.009	5.77E-19	0.56	-0.012	0.002	rs4251961	113590938	t	c	0.82	-0.021	2.03E-05	33,437	0.613	0.073
rs715	2	211251300	CPS1	t	c	0.68	0.009	1.98E-11	0.8	0.007	0.162	rs7607205	211197348	t	g	0.75	0.012	0.006	53,952	0.146	0.019
rs1476698	2	241945122	FARP2	a	g	0.65	0.006	2.24E-09	0.62	0.006	0.129	rs7578199	241841521	t	c	0.82	-0.015	0.002	103,601	0.165	0.019
rs1154988	3	137407881	PCCB	a	t	0.78	-0.01	9.64E-17	0.70	-0.001	0.763	rs1145101	137551976	t	c	0.15	0.016	0.002	144,095	0.649	0.328
rs16844401	4	3419450	HGFAC	a	g	0.08	0.015	1.74E-08	0.033	0.015	0.232	rs13147370	3252607	c	g	0.42	-0.009	0.030	166,843	0.032	0.000
rs1800789	4	155702193	FGB	a	g	0.21	0.031	1.68E-127	0.10	0.032	4.02E-07	rs4463047	155714983	t	c	0.87	0.041	4.63E-10	12,790	0.001	0.014
rs2106854	5	131797073	IRF1	t	c	0.21	-0.019	1.72E-48	0.24	-0.009	0.043	rs2706395	131824702	a	t	0.69	0.023	6.98E-08	27,629	0.924	0.214
rs11242111	5	131783957	IRF1	a	g	0.05	0.023	1.60E-21	0.37	-0.003	0.443	rs2706395	131824702	a	t	0.69	0.023	6.98E-08	40,745	0.008	0.050
rs2286503	7	22823131	TOMM7	t	c	0.36	-0.006	6.88E-09	0.68	-3E-04	0.946	rs2069827	22731981	t	g	0.02	0.036	0.012	91,150	0.031	-1.000
rs10226084	7	17964137	PRPS1L1	t	c	0.52	-0.007	5.05E-10	0.61	-0.004	0.358	rs17138358	17886778	c	g	0.54	-0.011	0.003	77,359	0.400	0.267
rs7464572	8	145093155	PLEC1	c	g	0.60	-0.007	1.33E-09	0.88	-0.002	0.738	rs11136341	145115531	a	g	0.47	-0.014	0.003	22,376	0.607	0.075
rs7896783	10	64832159	JMJD1C	a	g	0.48	-0.01	8.90E-22	0.32	-0.01	0.013	rs7896518	64774506	a	g	0.67	0.011	0.007	57,653	0.841	1.000
rs1019670	11	59697175	MS4A6A	a	t	0.36	-0.007	4.37E-09	0.10	-0.016	0.033	rs2081547	59746006	t	c	0.12	-0.015	0.009	48,831	0.591	0.390
rs7968440	12	49421008	DIP2B	a	g	0.64	0.006	2.74E-08	0.82	-1E-04	0.987	rs1362965	49608261	t	c	0.93	0.025	9.25E-4	187,253	0.319	0.032
rs434943	14	68383812	ACTN1	a	g	0.31	0.007	1.08E-08	0.15	-0.009	0.138	rs3809391	68330602	t	c	0.04	0.036	0.002	53,210	0.008	0.006
rs12915708	15	48835894	SPPL2A	c	g	0.30	-0.007	6.87E-10	0.10	-6E-04	0.925	rs8033085	48856352	t	c	0.08	-0.019	0.011	20,458	0.135	0.108
rs7204230	16	51749832	CHD9	t	c	0.7	0.008	1.18E-10	0.67	0.012	0.003	rs16952044	51757783	a	g	0.68	0.014	4.04E-4	7,951	1.000	1.000
rs10512597	17	70211428	CD300LF	t	c	0.18	-0.008	9.92E-09	0.64	-0.006	0.192	rs783240	70095693	a	g	0.52	0.018	0.005	115,735	0.010	0.000
rs4817986	21	39387382	PSMG1	t	g	0.28	-0.008	2.46E-11	0.11	-0.004	0.583	rs8130107	39347449	t	c	0.51	-0.012	0.002	39,933	0.050	0.049
rs6010044	22	49448804	SHANK3	a	c	0.8	-0.008	3.41E-08	0.88	0.009	0.134	rs5770957	49417151	t	c	0.09	0.051	5.3E-4	31,653	0.021	na

b)

SNP	CHR	POS	GENE	24 LEAD SNPs in EA					24 LEAD SNPs in Hispanics					24 "Proxy" SNPs in Hispanics								
				A1	A2	Freq	beta	P-value	A1	A2	Freq	beta	P-value	Chr	POS	A1	A2	Freq	beta in Hispa	P value in Hispa		
rs1938492	1	65890417	PDE4B	a	c	0.623	0.0081	5.28E-14							rs4384209	1	66051713	G	A	0.61	0.022	0.007
rs4129267	1	152692888	IL6R	t	c	0.392	-0.011	5.97E-27	T	C	0.47	-0.031	2.101E-05	rs8192284	1	152693594	C	A	0.47	-0.032	1.9E-05	
rs10157379	1	245672222	NLRP3	t	c	0.621	0.0099	1.15E-19	T	C	0.59	0.007	0.343	rs12070953	1	245681009	T	C	0.89	-0.043	0.005	
rs12712127	2	102093093	IL1R1	a	g	0.409	0.0058	2.72E-08	G	A	0.65	0.000	0.999	rs3917325	2	102160339	T	G	0.95	-0.049	0.002	
rs6734238	2	113557501	IL1RN	a	g	0.584	-0.009	5.77E-19	G	A	0.34	0.011	0.166	rs874898	2	113690667	G	C	0.77	-0.026	0.003	
rs715	2	211251300	CPS1	t	c	0.682	0.0087	1.98E-11	T	C	0.74	0.007	0.400	rs1588365	2	211087499	G	A	0.64	-0.025	9.7E-04	
rs1476698	2	241945122	FARP2	a	g	0.647	0.0065	2.24E-09	G	A	0.53	-0.013	0.066	rs4675973	2	241845768	T	C	0.47	-0.019	0.014	
rs1154988	3	137407881	PCCB	a	t	0.777	-0.01	9.64E-17	T	A	0.22	0.018	0.039	rs1154988	3	137407881	T	A	0.22	0.018	0.039	
rs16844401	4	3419450	HGFAC	a	g	0.077	0.0149	1.74E-08	G	A	0.90	-0.017	0.323	rs16844280	4	3378822	T	C	0.07	0.033	0.021	
rs1800789	4	155702193	FGF	a	g	0.21	0.0306	1.68E-127	G	A	0.85	-0.052	6.89E-07	rs4508864	4	155700739	T	C	0.13	0.063	4.77E-07	
rs2106854	5	131797073	IRF1	t	c	0.208	-0.019	1.72E-48	T	C	0.21	-0.024	0.007	rs2631362	5	131735192	G	A	0.28	-0.027	5.71E-04	
rs11242111	5	131783957	IRF1	a	g	0.051	0.0232	1.60E-21	G	A	0.91	0.001	0.917	rs2631362	5	131735192	G	A	0.28	-0.027	5.71E-04	
rs2286503	7	22823131	TOMM7	t	c	0.36	-0.006	6.88E-09	T	C	0.48	-0.002	0.757	rs1880241	7	22725994	G	A	0.67	-0.020	0.008	
rs10226084	7	17964137	PRPS1L1	t	c	0.523	-0.007	5.05E-10	T	C	0.49	-0.003	0.632	rs17345660	7	18151634	G	A	0.98	-0.069	0.006	
rs7464572	8	145093155	PLEC1	c	g	0.596	-0.007	1.33E-09	G	C	0.28	0.015	0.058	rs11786896	8	145090342	T	C	0.05	0.063	0.010	
rs7896783	10	64832159	JMJD1C	a	g	0.484	-0.01	8.90E-22	G	A	0.69	0.009	0.247	rs11817169	10	65026315	G	A	0.17	0.035	3.15E-04	
rs1019670	11	59697175	MS4A6A	a	t	0.363	-0.007	4.37E-09	T	A	0.78	-0.004	0.634	rs17154445	11	59552878	T	C	0.01	-0.095	0.003	
rs7968440	12	49421008	DIP2B	a	g	0.639	0.006	2.74E-08	G	A	0.22	-0.011	0.215	rs4132432	12	49276485	G	C	0.15	0.018	0.054	
rs434943	14	68383812	ACTN1	a	g	0.314	0.007	1.08E-08	G	A	0.72	-0.013	0.165	rs7141959	14	68427126	G	C	0.53	0.020	0.018	
rs12915708	15	48835894	SPPL2A	c	g	0.304	-0.007	6.87E-10	G	C	0.78	0.013	0.151	rs8023464	15	48659366	C	A	0.94	0.035	0.025	
rs7204230	16	51749832	CHD9	t	c	0.7	0.0078	1.18E-10	T	C	0.79	0.037	5.378E-05	rs8050349	16	51897377	T	C	0.18	-0.042	2.63E-05	
rs10512597	17	70211428	CD300LF	t	c	0.177	-0.008	9.92E-09	T	C	0.44	-0.007	0.350	rs492256	17	70115771	T	A	0.53	-0.019	0.011	
rs4817986	21	39387382	PSMG1	t	g	0.279	-0.008	2.46E-11	T	G	0.24	-0.025	0.011	rs8129630	21	39229095	G	A	0.02	0.077	0.003	
rs6010044	22	49448804	SHANK3	a	c	0.8	-0.008	3.41E-08	C	A	0.26	-0.011	0.215	rs6010065	22	49504883	G	C	0.54	0.016	0.042	

Supplementary Table S8: Results of pathway analyses using MAGENTA and GRAIL and expression quantitative trait locus (eQTL) analysis in human liver.

SNP	Band	Closest gene	P	Additional evidence	Candidate gene	Pathway
rs1938492	1p31.3	<i>LEPR</i>	5.28X10 ⁻¹⁴	Grail/Magenta eQTL_liver	<i>LEPR</i> <i>LEPR</i> (P=4.37x10 ⁻¹⁰)	Adipocytokine signaling pathway
rs4129267	1q21.3	<i>IL6R</i>	5.97X10 ⁻²⁷	Grail/Magenta	<i>IL6R</i>	Acute phase.R response signaling/JAK-STAT cascade
rs10157379	1q44	<i>NLRP3</i>	1.15X10 ⁻¹⁹	Grail	<i>NLRP3</i>	
rs12712127	2q11.2	<i>IL1R1/IL1R2</i>	2.72X10 ⁻⁰⁸	Grail/Magenta	<i>IL1R1</i>	Acute phase response signaling interleukin-1 receptor binding
rs6734238	2q13	<i>IL1F10/IL1RN</i>	5.77X10 ⁻¹⁹	Grail/Magenta	<i>IL1RN/IL1F10,IL1F5,IL1F8,IL1RN</i>	
rs715	2q34	<i>CPS1</i>	1.98X10 ⁻¹¹			
rs1476698	2q37.3	<i>FARP2</i>	2.24X10 ⁻⁰⁹			
rs1154988	3q22.3	<i>MSL2/PCCB</i>	9.64X10 ⁻¹⁷	eQTL_liver	<i>PCCB</i> (P=1.44x10 ⁻⁶) <i>MSL2L1</i> (P=3.91x10 ⁻¹⁴) <i>NGFRAP1</i> (P=7.61x10 ⁻¹²)	
rs16844401	4p16.2	<i>HGFAC/LRPAP1</i>	1.74X10 ⁻⁰⁸	Grail	<i>LRPAP1</i>	Acute phase response signaling
rs1800789	4q32.1	<i>FGB</i>	1.68X10 ⁻¹²⁷	Magenta eQTL_liver	<i>FGA,FGB</i> <i>FGB</i> (P=1.2x10 ⁻⁸)	
rs2106854	5q31.1	<i>C5orf56/IRF1</i>	1.72X10 ⁻⁴⁸			
rs11242111	5q31.1	<i>C5orf56/IRF1</i>	1.60X10 ⁻²¹			
rs2286503	7p15.3	<i>TOMM7</i>	6.88X10 ⁻⁰⁹	eQTL_liver	<i>TOMM7</i> (P=2.23x10 ⁻⁵)	
rs10226084	7p21.1	<i>SNX13/PRPS1L1</i>	5.05X10 ⁻¹⁰			
rs7464572	8q24.3	<i>PLEC1</i>	1.33X10 ⁻⁰⁹			
rs7896783	10q21.3	<i>JMJD1C</i>	8.90X10 ⁻²²			
rs1019670	11q12.1	<i>MS4A6A</i>	4.37X10 ⁻⁰⁹			
rs7968440	12q13.13	<i>DIP2B</i>	2.74X10 ⁻⁰⁸			
rs434943	14q24.1	<i>ACTN1</i>	1.08X10 ⁻⁰⁸	Magenta	<i>ACTN1</i>	Systemic Lupus Erythematosus
rs12915708	15q21.2	<i>SPPL2A</i>	6.87X10 ⁻¹⁰			
rs7204230	16q12.2	<i>CHD9</i>	1.18X10 ⁻¹⁰			
rs10512597	17q25.1	<i>CD300LF</i>	9.92X10 ⁻⁰⁹			
rs4817986	21q22.2	<i>PSMG1</i>	2.46X10 ⁻¹¹			
rs6010044	22q13.33	<i>SHANK3/ARSA</i>	3.41X10 ⁻⁰⁸	Magenta	<i>CPT1B</i>	Adipocytokine signaling pathway

Supplementary Table S9: Extended list of the lead candidate SNPs, including those obtained through the genome-wide association meta-analysis (the 24 “lead-SNPs”) plus those candidate SNPs obtained through pathway analyses in GRAIL and MAGENTA.

Category	SNP	Chr	A		Freq1	Effect	StdErr	P-value	GRAIL.FDR	GRAIL.GWAS	MAGENTA.GENES.PATHWAYS
			1	2							
Genome-wide Significant	rs1938492	1	a	c	0.62	0.008	0.001	5.28E-14	-	0.042000252@LEPR	LEPR@KEGG-KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY
Genome-wide Significant	rs4129267	1	t	c	0.39	-0.011	0.001	5.97E-27			
Genome-wide Significant	rs10157379	1	t	c	0.62	0.010	0.001	1.15E-19	-	0.026496169@NLRP3	-
Genome-wide Significant	rs12712127	2	a	g	0.41	0.006	0.001	2.72E-08	-	0.001451751@IL1R1	IL1R1@Ingenuity-Acute.Phase.Response.Signaling
Genome-wide Significant	rs6734238	2	a	g	0.58	-0.009	0.001	5.77E-19	-	0.000351036@IL1RN	IL1F10,IL1F5,IL1F8,IL1RN@GOTERM-interleukin-1.receptor.binding,PANTHER_MOLECULAR_FUNCTION-Interleukin
Genome-wide Significant	rs715	2	t	c	0.68	0.009	0.001	1.98E-11	-	-	-
Genome-wide Significant	rs1476698	2	a	g	0.65	0.007	0.001	2.24E-09	-	-	-
Genome-wide Significant	rs1154988	3	a	t	0.78	-0.010	0.001	9.64E-17	-	-	-
Genome-wide Significant	rs16844401	4	a	g	0.08	0.015	0.003	1.74E-08			
Genome-wide Significant	rs1800789	4	a	g	0.21	0.031	0.001	1.68E-127	-	-	FGA,FGB@Ingenuity-Acute.Phase.Response.Signaling
Genome-wide Significant	rs11242111	5	a	g	0.05	0.023	0.002	1.60E-21			
Genome-wide Significant	rs2106854	5	t	c	0.21	-0.019	0.001	1.72E-48			
Genome-wide Significant	rs10226084	7	t	c	0.52	-0.007	0.001	5.05E-10	-	-	-
Genome-wide Significant	rs2286503	7	t	c	0.36	-0.006	0.001	6.88E-09			
Genome-wide Significant	rs7464572	8	c	g	0.60	-0.007	0.001	1.33E-09	-	-	-
Genome-wide Significant	rs7896783	10	a	g	0.48	-0.010	0.001	8.90E-22	-	-	-
Genome-wide Significant	rs1019670	11	a	t	0.36	-0.007	0.001	4.37E-09	-	-	-
Genome-wide Significant	rs7968440	12	a	g	0.64	0.006	0.001	2.74E-08			
Genome-wide Significant	rs434943	14	a	g	0.31	0.007	0.001	1.08E-08	-	-	ACTN1@KEGG-KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS
Genome-wide Significant	rs12915708	15	c	g	0.30	-0.007	0.001	6.87E-10			
Genome-wide Significant	rs7204230	16	t	c	0.70	0.008	0.001	1.18E-10	-	-	-
Genome-wide Significant	rs10512597	17	t	c	0.18	-0.008	0.001	9.92E-09	-	-	-
Genome-wide Significant	rs4817986	21	t	g	0.28	-0.008	0.001	2.46E-11	-	-	-
Genome-wide Significant	rs6010044	22	a	c	0.80	-0.008	0.001	3.41E-08	-	-	CPT1B@KEGG-KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY
GRAIL-FDR	rs2272163	3	a	c	0.38	-0.005	0.001	6.10E-05	0.044313377@ROBO2	-	-
GRAIL-FDR	rs2161374	5	t	c	0.45	-0.005	0.001	2.22E-06	0.025228345@DUSP1	-	-
GRAIL-FDR	rs732839	8	a	g	0.23	0.006	0.001	1.11E-05	0.04285248@PPP1R3B	-	-
GRAIL-FDR	rs10814489	9	a	g	0.35	-0.005	0.001	7.40E-06	0.045550713@PAX5	-	-
GRAIL-FDR	rs11186629	10	a	t	0.70	0.005	0.001	3.08E-05	0.002919608@PPP1R3C	-	-
GRAIL-FDR	rs17101410	10	t	c	0.09	-0.008	0.002	8.89E-06	0.02878597@BRWD2	-	-

GRAIL-FDR	rs224628	11	t	c	0.84	-0.006	0.001	2.25E-05	0.041547845@PAX6	-	-
GRAIL-FDR/MAGENTA-FDR	rs7118744	11	a	g	0.38	0.005	0.001	1.15E-05	0.037380292@ETS1	-	ETS1@Ingenuity-GM-CSF.Signaling
GRAIL-FDR	rs1871143	12	t	g	0.22	0.006	0.001	1.23E-06	0.009746531@GYS2	-	-
GRAIL-FDR	rs1887826	13	a	g	0.53	-0.004	0.001	1.19E-04	0.032901685@ATXN8OS	-	-
GRAIL-FDR	rs3803522	15	a	g	0.80	-0.005	0.001	2.89E-05	0.030742241@MAP2K5	-	-
GRAIL-FDR	rs4334315	16	a	t	0.70	-0.006	0.002	1.37E-05	0.021271154@MAF	-	-
GRAIL-FDR	rs11079035	17	a	g	0.17	0.006	0.001	6.43E-06	0.00416818@STAT5B	-	-
GRAIL-FDR/MAGENTA-FDR	rs3817294	17	a	g	0.39	-0.006	0.001	7.73E-07	0.03318157@SOCS3	-	SOCS3@Ingenuity-IL-10.Signaling,KEGG- KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY,PANTHER_BIOLOGICAL L_PROCESS-JAK-STAT_cascade
GRAIL-FDR/MAGENTA-FDR	rs11080606	18	t	c	0.70	0.006	0.001	6.40E-07	0.047692543@PTPN2	-	PTPN2@PANTHER_BIOLOGICAL_PROCESS-JAK-STAT_cascade
GRAIL-FDR	rs1460191	18	a	c	0.18	0.006	0.001	3.11E-05	0.005129877@DCC	-	-
GRAIL-FDR	rs1800961	20	t	c	0.03	-0.016	0.003	1.60E-06	0.033484871@HNF4A	-	-
GRAIL-FDR	rs5765575	22	t	g	0.66	0.005	0.001	5.15E-05	0.017445336@ATXN10	-	-
MAGENTA-FDR	rs2404715	1	t	c	0.09	-0.007	0.002	1.61E-04	-	-	PRKAA2@KEGG-KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY IL6R@Ingenuity- Acute.Phase.Response.Signaling,PANTHER_BIOLOGICAL_PROCESS- JAK-STAT_cascade
MAGENTA-FDR	rs8192284	1	a	c	0.61	0.011	0.001	6.75E-27	-	0.001503629@IL6R	VAMP8@Panther-Thyrotropin- releasing_hormone_receptor_signaling_pathway
MAGENTA-FDR	rs10206961	2	t	c	0.39	0.004	0.001	0.000102	-	-	IL1A,IL1B@GOTERM-interleukin-1.receptor.binding
MAGENTA-FDR	rs12053091	2	t	c	0.74	0.006	0.001	2.15E-06	-	-	IL1F6@GOTERM-interleukin-1.receptor.binding
MAGENTA-FDR	rs11689250	2	a	g	0.67	0.006	0.001	1.48E-07	-	-	ITIH3@Ingenuity-Acute.Phase.Response.Signaling
MAGENTA-FDR	rs11235	3	t	c	0.58	-0.004	0.001	7.26E-05	-	-	H1FOO@PANTHER_MOLECULAR_FUNCTION-Histone
MAGENTA-FDR	rs1872111	3	a	g	0.88	-0.008	0.002	6.94E-07	-	-	FGG@Ingenuity-Acute.Phase.Response.Signaling
MAGENTA-FDR	rs2227401	4	t	c	0.21	0.031	0.001	2.32E-127	-	-	C9@Ingenuity-Acute.Phase.Response.Signaling
MAGENTA-FDR	rs10070876	5	t	c	0.91	0.009	0.002	5.04E-05	-	-	ACSL6,IL3@Ingenuity-Fc.Epsilon.RI.Signaling,KEGG- KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY,KEGG- KEGG_ASTHMA,PANTHER_BIOLOGICAL_PROCESS-JAK-STAT_cascade
MAGENTA-FDR	rs10078535	5	a	g	0.97	-0.017	0.003	1.00E-08	-	-	CSF2@Ingenuity-Fc.Epsilon.RI.Signaling,Ingenuity-GM- CSF.Signaling,PANTHER_BIOLOGICAL_PROCESS-JAK-STAT_cascade
MAGENTA-FDR	rs3843502	5	a	g	0.03	0.017	0.003	1.05E-08	-	-	IL5@Ingenuity-Fc.Epsilon.RI.Signaling,KEGG- KEGG_ASTHMA,PANTHER_BIOLOGICAL_PROCESS-JAK- STAT_cascade,PANTHER_MOLECULAR_FUNCTION-Interleukin
MAGENTA-FDR	rs4705952	5	a	g	0.78	0.013	0.001	4.26E-24	-	-	IL13,IL4@Ingenuity-Fc.Epsilon.RI.Signaling,KEGG- KEGG_ASTHMA,PANTHER_BIOLOGICAL_PROCESS-JAK- STAT_cascade,PANTHER_MOLECULAR_FUNCTION-Interleukin
MAGENTA-FDR	rs2244012	5	a	g	0.79	0.011	0.001	1.07E-16	-	-	HIST1H2AA@KEGG- KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS,PANTHER_MOLECULAR_F UNCTION-Histone
MAGENTA-FDR	rs1408268	6	a	t	0.24	0.007	0.001	6.40E-08	-	-	HIST1H1A,HIST1H1C,HIST1H1E,HIST1H2AB,HIST1H2AC,HIST1H2BB,HIS T1H2BC,HIST1H2BD,HIST1H2BE,HIST1H2BF,HIST1H3B,HIST1H4B,HIST
MAGENTA-FDR	rs1572982	6	a	g	0.46	0.005	0.001	6.16E-06	-	-	

Supplementary Table S10: Predicted function of SNPs in the 250 kb window surrounding the fibrinogen genes according to Snp137 database (only SNPs included in the meta-analysis that had association p-values with fibrinogen plasma levels $< 10^{-6}$ are included in this table). In addition, significant associations between SNPs located in the same region and Fibrinogen transcripts are also included, to show functional effect on transcript level. Both missense mutations (rs6050 and rs4220) were predicted to be benign according to PolyPhen scores. Rs7659024 has been associated with venous thromboembolism¹⁰⁷.


SNP	chrom	position	Function	Tissue	eSNP p-value	Transcript
rs2404478	4	155408038	unknown	Liver (ASAP)	1,90E-03	FGB
rs871540	4	155409030	unknown	Liver (ASAP)	1,90E-03	FGB
rs10019863	4	155427505	unknown	Liver (ASAP)	3,39E-03	FGG
rs4508864	4	155481289	unknown	Liver (Schadt)	1,20E-08	FGB
rs6050	4	155507590	missense			
rs7659024	4	155520930	unknown	Liver(Greenawalt)	2,17E-16	FGG
rs10517596	4	155627814	unknown	Liver(UChicago)	8,08E-03	FGA
rs17031728	4	155412581	5PRIME_UTR			
rs2227401	4	155486381	3PRIME_UTR			
rs4220	4	155491759	missense	Liver(Greenawalt)	1,38E-20	FGB

Supplementary Table S11: Results of the associations between the lead-SNPs and different stroke phenotypes. These results are based on 790 cardioembolic stroke cases, 844 large vessel disease ischaemic stroke cases and 580 small vessel disease ischaemic stroke cases.

SNP	Chrom	Position	Allele1	Allele2	Freq1	CE			LAA			SVD		
						OR	SE	P	OR	SE	P	OR	SE	P
rs4817986	21	39387382	t	g	0.27	1.11	0.06	0.10	1.06	0.06	0.33	0.92	0.07	0.26
rs434943	14	68383812	a	g	0.33	1.05	0.06	0.40	0.97	0.06	0.55	1.07	0.07	0.33
rs1154988	3	137407881	a	t	0.78	0.89	0.07	0.07	0.94	0.06	0.31	0.97	0.07	0.72
rs7896783	10	64832159	a	g	0.48	0.98	0.06	0.76	1.08	0.05	0.17	0.88	0.06	0.04
rs7464572	8	145093155	c	g	0.60	1.03	0.06	0.56	0.93	0.05	0.21	1.07	0.06	0.26
rs2286503	7	22823131	t	c	0.36	0.93	0.06	0.20	0.93	0.06	0.20	1.00	0.06	0.96
rs16844401	4	3419450	a	g	0.07	0.94	0.12	0.62	0.98	0.11	0.82	0.87	0.13	0.28
rs7968440	12	49421008	a	g	0.66	1.14	0.06	0.03	0.91	0.06	0.11	1.03	0.07	0.66
rs1938492	1	65890417	a	c	0.62	0.96	0.06	0.53	1.05	0.06	0.37	0.94	0.06	0.30
rs715	2	211251300	t	c	0.66	1.06	0.06	0.36	1.00	0.06	0.95	1.01	0.07	0.93
rs6010044	22	49448804	a	c	0.75	0.91	0.07	0.14	1.03	0.07	0.70	0.98	0.08	0.80
rs11242111	5	131783957	a	g	0.05	1.19	0.13	0.17	1.20	0.12	0.15	0.70	0.18	0.04
rs12915708	15	48835894	c	g	0.30	1.13	0.06	0.04	0.97	0.06	0.60	0.98	0.07	0.80
rs12712127	2	102093093	a	g	0.41	1.00	0.06	0.97	1.07	0.05	0.21	1.03	0.06	0.66
rs6734238	2	113557501	a	g	0.60	1.07	0.06	0.24	1.00	0.05	0.98	1.00	0.06	0.99
rs10512597	17	70211428	t	c	0.18	0.90	0.07	0.17	0.97	0.07	0.68	0.98	0.08	0.79
rs1800789	4	155702193	a	g	0.21	1.07	0.07	0.34	1.04	0.07	0.56	0.97	0.08	0.74
rs1019670	11	59697175	a	t	0.35	1.02	0.06	0.70	0.92	0.06	0.18	0.95	0.07	0.44
rs2106854	5	131797073	t	c	0.20	0.98	0.07	0.73	0.98	0.07	0.80	0.92	0.08	0.30
rs10157379	1	245672222	t	c	0.63	1.00	0.06	0.95	1.06	0.06	0.29	1.03	0.06	0.66
rs7204230	16	51749832	t	c	0.70	1.05	0.06	0.39	1.09	0.06	0.12	1.00	0.07	0.95
rs4129267	1	152692888	t	c	0.40	0.98	0.06	0.72	1.04	0.05	0.44	0.95	0.06	0.42
rs10226084	7	17964137	t	c	0.52	1.09	0.06	0.10	0.90	0.05	0.06	1.06	0.06	0.36
rs1476698	2	241945122	a	g	0.65	1.02	0.06	0.73	1.08	0.06	0.16	0.98	0.06	0.71


Abbreviations: Chrom= chromosome; Freq1= frequency of allele1; OR= Odds ratio; SE= Standard error; CE= cardioembolic stroke; LAA= Large vessel disease ischaemic stroke; SVD= small vessel disease ischaemic stroke.

Supplementary Figure S1: analysis conditional on the 23 lead SNPs (European samples). The main signal was located in the *IRF1* locus about 25 kb upstream of *SLC22A5*, indicating that the *IRF1* locus harbors 2 independent signals located 13 kb apart ($r^2 = 0.010$ according to 1000 Genomes Map Pilot 1) represented by rs11242111 and rs2106854. A significant signal was also found in *FGA* gene (rs2070016, $P = 3.9 \times 10^{-8}$) which showed evidence of correlation with the lead SNP rs1800789 in *FGB* ($r^2 = 0.364$ according to 1000 Genomes Map Pilot 1);




Supplementary Figure S2: Regional Plots for the 23 loci found in the discovery European meta-analysis (pdf attached).


rs4129267 – European




rs4129267 – African




rs10157379 – European




rs10157379 – African




rs1938492 – European




rs1938492 – African




rs12712127 – European




rs12712127 – African




rs6734238 – European




rs6734238 – African




rs715 – European




rs715 – African




rs1476698 – European




rs1476698 – African




rs4817986 – European




rs4817986 – African




rs6010044 – European




rs6010044 – African




rs1019670 – European




rs1019670 – African




rs7968440 – European




rs7968440 – African




rs434943 – European




rs434943 – African




rs12915708 – European




rs12915708 – African




rs7204230 – European




rs7204230 – African




rs10512597 – European




rs10512597 – African




rs1154988 – European




rs1154988 – African




rs1800789 – European




rs1800789 – African




rs16844401 – European




rs16844401 – African




rs11242111 – European




rs11242111 – African




rs2106854 – European




rs2106854 – African




rs10226084 – European




rs10226084 – African




rs2286503 – European




rs2286503 – African




rs7464572 – European




rs7464572 – African



Supplementary Figure S3: Manhattan plot showing the results for the meta-analysis in (A) African American and (B) Hispanic Samples.



Supplementary Figure S4: QQ-plots for the meta-analysis in (A) European, (B) African American, and (C) Hispanic Samples.



Supplementary references

1. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. *Prev Med.* 1975;4:518-525.
2. Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, Buring JE. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. *Clin Chem.* 2008;54:249-255.
3. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M, Lai S, Usala G, Lai M, Loi P, Mameli C, Vacca L, Deiana M, Olla N, Masala M, Cao A, Najjar SS, Terracciano A, Nedorezov T, Sharov A, Zonderman AB, Abecasis GR, Costa P, Lakatta E, Schlessinger D. Heritability of cardiovascular and personality traits in 6,148 Sardinians. *PLoS Genet.* 2006;2:e132.
4. Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, Kuipers EJ, Nijsten TE, Stricker BH, Tiemeier H, Uitterlinden AG, Vernooij MW, Witteman JC. The Rotterdam Study: 2012 objectives and design update. *Eur J Epidemiol.* 2012;26:657-686.
5. John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E, Haertel U, Hense HW, Haerting J, Willich S, Kessler C. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. *Soz Praventivmed.* 2001;46:186-194.
6. Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, Havemann C, Ittermann T, Schipf S, Haring R, Baumeister SE, Wallaschofski H, Nauck M, Frick S, Arnold A, Junger M, Mayerle J, Kraft M, Lerch MM, Dorr M, Reffellmann T, Empen K, Felix SB, Obst A, Koch B, Glaser S, Ewert R, Fietze I, Penzel T, Doren M, Rathmann W, Haerting J, Hannemann M, Ropcke J, Schminke U, Jurgens C, Tost F, Rettig R, Kors JA, Ungerer S, Hegenscheid K, Kuhn JP, Kuhn J, Hosten N, Puls R, Henke J, Gloger O, Teumer A, Homuth G, Volker U, Schwahn C, Holtfreter B, Polzer I, Kohlmann T, Grabe HJ, Roszkopf D, Kroemer HK, Kocher T, Biffar R, John U, Hoffmann W. Cohort profile: the study of health in Pomerania. *Int J Epidemiol.* 2011;40:294-307.
7. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR, Jr., Liu K, Savage PJ. CARDIA: study design, recruitment, and some characteristics of the examined subjects. *J Clin Epidemiol.* 1988;41:1105-1116.
8. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet.* 2002;360:1623-1630.
9. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROSpective Study of Pravastatin in the Elderly at Risk. *Am J Cardiol.* 1999;84:1192-1197.
10. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al. The Cardiovascular Health Study: design and rationale. *Ann Epidemiol.* 1991;1:263-276.
11. Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort Profile: The Lothian Birth Cohorts of 1921 and 1936. *Int J Epidemiol.*

12. Deary IJ, Gow AJ, Taylor MD, Corley J, Brett C, Wilson V, Campbell H, Whalley LJ, Visscher PM, Porteous DJ, Starr JM. The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. *BMC Geriatr.* 2007;7:28.
13. Deary IJ, Whiteman MC, Starr JM, Whalley LJ, Fox HC. The impact of childhood intelligence on later life: following up the Scottish mental surveys of 1932 and 1947. *J Pers Soc Psychol.* 2004;86:130-147.
14. Antoni G, Oudot-Mellakh T, Dimitromanolakis A, Germain M, Cohen W, Wells P, Lathrop M, Gagnon F, Morange PE, Tregouet DA. Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. *BMC Med Genet.* 2011;12:102.
15. Rudan I, Marusic A, Jankovic S, Rotim K, Boban M, Lauc G, Grkovic I, Dogas Z, Zemunik T, Vatauvuk Z, Bencic G, Rudan D, Mulic R, Krzelj V, Terzic J, Stojanovic D, Puntaric D, Bilic E, Ropac D, Vorko-Jovic A, Znaor A, Stevanovic R, Biloglav Z, Polasek O. "10001 Dalmatians:" Croatia launches its national biobank. *Croat Med J.* 2009;50:4-6.
16. Zemunik T, Boban M, Lauc G, Jankovic S, Rotim K, Vatauvuk Z, Bencic G, Dogas Z, Boraska V, Torlak V, Susac J, Zobic I, Rudan D, Pulanic D, Modun D, Mudnic I, Gunjaca G, Budimir D, Hayward C, Vitart V, Wright AF, Campbell H, Rudan I. Genome-wide association study of biochemical traits in Korcula Island, Croatia. *Croat Med J.* 2009;50:23-33.
17. McQuillan R, Leutenegger AL, Abdel-Rahman R, Franklin CS, Pericic M, Barac-Lauc L, Smolej-Narancic N, Janicijevic B, Polasek O, Tenesa A, Macleod AK, Farrington SM, Rudan P, Hayward C, Vitart V, Rudan I, Wild SH, Dunlop MG, Wright AF, Campbell H, Wilson JF. Runs of homozygosity in European populations. *Am J Hum Genet.* 2008;83:359-372.
18. Strachan DP, Rudnicka AR, Power C, Shepherd P, Fuller E, Davis A, Gibb I, Kumari M, Rumley A, Macfarlane GJ, Rahi J, Rodgers B, Stansfeld S. Lifecourse influences on health among British adults: effects of region of residence in childhood and adulthood. *Int J Epidemiol.* 2007;36:522-531.
19. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007;447:661-678.
20. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat Genet.* 2009;41:703-707.
21. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WO. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med.* 2010;363:1211-1221.
22. Holle R, Happich M, Lowel H, Wichmann HE. KORA--a research platform for population based health research. *Gesundheitswesen.* 2005;67 Suppl 1:S19-25.
23. Wichmann HE, Gieger C, Illig T. KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes. *Gesundheitswesen.* 2005;67 Suppl 1:S26-30.
24. Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, Harris TB, Guralnik JM. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. *Journal of the American Geriatrics Society.* 2000;48:1618-1625.
25. Andrew T, Hart DJ, Snieder H, de Lange M, Spector TD, MacGregor AJ. Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. *Twin Res.* 2001;4:464-477.

26. Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG. Trajectories of growth among children who have coronary events as adults. *N Engl J Med*. 2005;353:1802-1809.
27. Eriksson JG, Osmond C, Kajantie E, Forsen TJ, Barker DJ. Patterns of growth among children who later develop type 2 diabetes or its risk factors. *Diabetologia*. 2006;49:2853-2858.
28. Willemsen G, de Geus EJ, Bartels M, van Beijsterveldt CE, Brooks AI, Estourgie-van Burk GF, Fugman DA, Hoekstra C, Hottenga JJ, Klufft K, Meijer P, Montgomery GW, Rizzu P, Sondervan D, Smit AB, Spijker S, Suchiman HE, Tischfield JA, Lehner T, Slagboom PE, Boomsma DI. The Netherlands Twin Register biobank: a resource for genetic epidemiological studies. *Twin Res Hum Genet*. 2010;13:231-245.
29. ARIC. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am J Epidemiol*. 1989;129:687-702.
30. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR, Jr., Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-ethnic study of atherosclerosis: objectives and design. *Am J Epidemiol*. 2002;156:871-881.
31. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. *JAMA*. 2006;295:1420-1427.
32. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. *Control Clin Trials*. 1998;19:61-109.
33. Redline S, Tishler PV, Tosteson TD, Williamson J, Kump K, Browner I, Ferrette V, Krejci P. The familial aggregation of obstructive sleep apnea. *Am J Respir Crit Care Med*. 1995;151:682-687.
34. Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]. *Acta Haematol*. 1957;17:237-246.
35. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. *JAMA*. 1987;258:1183-1186.
36. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. *Clin Chem*. 1995;41:264-270.
37. Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. *Circulation*. 2007;115:996-1003.
38. Dunn EJ, Ariens RA, de Lange M, Snieder H, Turney JH, Spector TD, Grant PJ. Genetics of fibrin clot structure: a twin study. *Blood*. 2004;103:1735-1740.
39. Clauss A. [Rapid physiological coagulation method in determination of fibrinogen.]. *Acta Haematol*. 1957;17:237-246.
40. Houlihan LM, Davies G, Tenesa A, Harris SE, Luciano M, Gow AJ, McGhee KA, Liewald DC, Porteous DJ, Starr JM, Lowe GD, Visscher PM, Deary IJ. Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. *Am J Hum Genet*. 2010;86:626-631.
41. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81:559-575.

42. Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, Rafferty I, Lauretani F, Murray A, Gibbs JR, Paolisso G, Rafiq S, Simon-Sanchez J, Lango H, Scholz S, Weedon MN, Arepalli S, Rice N, Washecka N, Hurst A, Britton A, Henley W, van de Leemput J, Li R, Newman AB, Tranah G, Harris T, Panicker V, Dayan C, Bennett A, McCarthy MI, Ruukonen A, Jarvelin MR, Guralnik J, Bandinelli S, Frayling TM, Singleton A, Ferrucci L. A genome-wide association study identifies protein quantitative trait loci (pQTLs). *PLoS Genet*. 2008;4:e1000072.
43. Teo YY, Inouye M, Small KS, Gwilliam R, Deloukas P, Kwiatkowski DP, Clark TG. A genotype calling algorithm for the Illumina BeadArray platform. *Bioinformatics*. 2007;23:2741-2746.
44. Suhre K, Shin SY, Petersen AK, Mohny RP, Meredith D, Wagele B, Altmaier E, Deloukas P, Erdmann J, Grundberg E, Hammond CJ, de Angelis MH, Kastenmuller G, Kottgen A, Kronenberg F, Mangino M, Meisinger C, Meitinger T, Mewes HW, Milburn MV, Prehn C, Raffler J, Ried JS, Romisch-Margl W, Samani NJ, Small KS, Wichmann HE, Zhai G, Illig T, Spector TD, Adamski J, Soranzo N, Gieger C. Human metabolic individuality in biomedical and pharmaceutical research. *Nature*.477:54-60.
45. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006;38:904-909.
46. Li Y, Abecasis GR. Mach 1.0: Rapid haplotype reconstruction and missing genotype inference. *Am J Hum Genet*. Vol S79; 2006:2290
47. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, Hubbell E, Veitch J, Collins PJ, Darvishi K, Lee C, Nizzari MM, Gabriel SB, Purcell S, Daly MJ, Altshuler D. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. *Nat Genet*. 2008;40:1253-1260.
48. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, de Bakker PI, Maller JB, Kirby A, Elliott AL, Parkin M, Hubbell E, Webster T, Mei R, Veitch J, Collins PJ, Handsaker R, Lincoln S, Nizzari M, Blume J, Jones KW, Rava R, Daly MJ, Gabriel SB, Altshuler D. Integrated detection and population-genetic analysis of SNPs and copy number variation. *Nat Genet*. 2008;40:1166-1174.
49. McPeck MS, Sun L. Statistical tests for detection of misspecified relationships by use of genome-screen data. *Am J Hum Genet*. 2000;66:1076-1094.
50. Huang L, Li Y, Singleton AB, Hardy JA, Abecasis G, Rosenberg NA, Scheet P. Genotype-imputation accuracy across worldwide human populations. *Am J Hum Genet*. 2009;84:235-250.
51. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinformatics*. 2010;11:134.
52. Abecasis GR, Cardon LR, Cookson WO, Sham PC, Cherny SS. Association analysis in a variance components framework. *Genet Epidemiol*. 2001;21 Suppl 1:S341-346.
53. Chen MH, Yang Q. GWAFA: an R package for genome-wide association analyses with family data. *Bioinformatics*.26:580-581.
54. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN, Chandrupatla HR, Hansen M, Ajmal S, Papanicolaou GJ, Guo Y, Li M, Derohannessian S, de Bakker PI, Bailey SD, Montpetit A, Edmondson AC, Taylor K, Gai X, Wang SS, Fornage M, Shaikh T, Groop L, Boehnke M, Hall AS, Hattersley AT, Frackelton E, Patterson N, Chiang CW, Kim CE, Fabsitz RR, Ouwehand W, Price AL, Munroe P, Caulfield M, Drake T, Boerwinkle E, Reich D, Whitehead AS, Cappola TP, Samani NJ, Lusk AJ, Schadt E, Wilson JG, Koenig W, McCarthy MI, Kathiresan S, Gabriel SB, Hakonarson H, Anand SS, Reilly M, Engert JC, Nickerson DA, Rader DJ,

Hirschhorn JN, Fitzgerald GA. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. *PLoS One*. 2008;3:e3583.

55. Benjamini Y, Hochberg Y. *Controlling the false discovery rate: a practical and powerful approach to multiple testing*. Vol 57; 1995.
56. Folkersen L, Wagsater D, Paloschi V, Jackson V, Petrini J, Kurtovic S, Maleki S, Eriksson MJ, Caidahl K, Hamsten A, Michel JB, Liska J, Gabrielsen A, Franco-Cereceda A, Eriksson P. Unraveling the divergent gene expression profiles in bicuspid and tricuspid aortic valve patients with thoracic aortic dilatation - the ASAP study. *Mol Med*.
57. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet*. 1998;62:1198-1211.
58. Keller MC, Medland SE, Duncan LE, Hatemi PK, Neale MC, Maes HH, Eaves LJ. Modeling extended twin family data I: description of the Cascade model. *Twin Res Hum Genet*. 2009;12:8-18.
59. Maes HH, Neale MC, Medland SE, Keller MC, Martin NG, Heath AC, Eaves LJ. Flexible Mx specification of various extended twin kinship designs. *Twin Res Hum Genet*. 2009;12:26-34.
60. Neale MC, Boker SM, Xie G, Maes HH. *Mx: Statistical Modeling, 7 ed*. Richmond, Virginia: Virginia Commonwealth University; 2006.
61. Neale MC, Walters EE, Eaves LJ, Maes HH, Kendler KS. Multivariate genetic analysis of twin-family data on fears: Mx models. *Behav Genet*. 1994;24:119-139.
62. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sober S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH, Sjogren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, Lehtimaki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uitterwaal CS, Adeyemo A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND, Aspelund T, Garcia M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC, Kahonen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Bolton JA, Kottgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grassler J, Groop L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Artigas MS, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y, Ogiwara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stancakova A, Raffel LJ, Yao J, Kathiresan S, O'Donnell CJ, Schwartz SM, Ikram MA, Longstreth WT, Jr., Mosley TH, Seshadri S, Shrine NR, Wain LV, Morken MA, Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani KR, Yajnik CS, Hofman A,

Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ, Lyttikainen LP, Soininen P, Tukiainen T, Wurtz P, Ong RT, Dorr M, Kroemer HK, Volker U, Volzke H, Galan P, Herberg S, Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MV, Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, Schwarz PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Tai ES, Cooper RS, Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen D, Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker PM, Bandinelli S, Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller PP, Elosua R, Soranzo N, Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boerwinkle E, Vasana RS, Boehnke M, Larson MG, Jarvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn CM, Newton-Cheh C, Levy D, Caulfield MJ, Johnson T, Tang H, Knowles J, Hlatky M, Fortmann S, Assimes TL, Quertermous T, Go A, Iribarren C, Absher D, Risch N, Myers R, Sidney S, Ziegler A, Schillert A, Bickel C, Sinning C, Rupprecht HJ, Lackner K, Wild P, Schnabel R, Blankenberg S, Zeller T, Munzel T, Perret C, Cambien F, Tiret L, Nicaud V, Proust C, Uitterlinden A, van Duijn C, Witteman J, Cupples LA, Demissie-Banjaw S, Ramachandran V, Smith A, Folsom A, Morrison A, Chen IY, Bis J, Volcik K, Rice K, Taylor KD, Marcianti K, Smith N, Glazer N, Heckbert S, Harris T, Lumley T, Kong A, Thorleifsson G, Thorgeirsson G, Holm H, Gulcher JR, Stefansson K, Andersen K, Gretarsdottir S, Thorsteinsdottir U, Preuss M, Schreiber S, Konig IR, Lieb W, Hengstenberg C, Schunkert H, Fischer M, Grosshennig A, Medack A, Stark K, Linsel-Nitschke P, Bruse P, Aherrahrou Z, Peters A, Loley C, Willenborg C, Nahrstedt J, Freyer J, Gulde S, Doering A, Meisinger C, Klopp N, Illig T, Meinitzer A, Tomaschitz A, Halperin E, Dobnig H, Scharnagl H, Kleber M, Laaksonen R, Pilz S, Grammer TB, Stojakovic T, Renner W, Marz W, Boehm BO, Winkelmann BR, Winkler K, Hoffmann MM, Siscovick DS, Musunuru K, Barbalic M, Guiducci C, Burt N, Gabriel SB, Stewart AF, Wells GA, Chen L, Jarinova O, Roberts R, McPherson R, Dandona S, Pichard AD, Rader DJ, Devaney J, Lindsay JM, Kent KM, Qu L, Satler L, Burnett MS, Li M, Reilly MP, Wilensky R, Waksman R, Epstein S, Matthai W, Knouff CW, Waterworth DM, Hakonarson HH, Walker MC, Hall AS, Balmforth AJ, Wright BJ, Nelson C, Thompson JR, Ball SG, Felix JF, Demissie S, Loehr LR, Rosamond WD, Folsom AR, Benjamin E, Aulchenko YS, Haritunians T, Couper D, Murabito J, Wang YA, Stricker BH, Gottdiener JS, Chang PP, Willerson JT, Boger CA, Fuchsberger C, Gao X, Yang Q, Schmidt H, Ketkar S, Pare G, Atkinson EJ, Lohman K, Cornelis MC, Probst-Hensch NM, Kronenberg F, Tonjes A, Eiriksdottir G, Launer LJ, Rumpersaud E, Mitchell BD, Struchalin M, Cavalieri M, Giallauria F, Metter J, de Boer J, Siscovick D, Zillikens MC, Feitosa M, Province M, de Andrade M, Turner ST, Wild PS, Schnabel RB, Wilde S, Munzel TF, Leak TS, Koenig W, Zgaga L, Zemunik T, Kolcic I, Minelli C, Hu FB, Johansson A, Zaboli G, Ellinghaus D, Imboden M, Nitsch D, Brandstatter A, Kollerits B, Kedenko L, Magi R, Stumvoll M, Kovacs P, Boban M, Campbell S, Endlich K, Nauck M, Badola S, Curhan GC, Franke A, Rochat T, Paulweber B, Wang W, Schmidt R, Shlipak MG, Borecki I, Kramer BK, Gyllensten U, Hastie N, Heid IM, Fox CS, Felix SB, Watzinger N, Homuth G, Aragam J, Zweiker R, Lind L, Rodeheffer RJ, Greiser KH, Deckers JW, Stritzke J, Lackner KJ, Ingelsson E, Kullo I, Haerting J, Reffelmann T, Redfield MM, Werdan K, Mitchell GF, Arnett DK, Blettner M, Friedrich N, Benjamin EJ, Lord GM, Gale DP, Wass MN, Ahmadi KR, Beckmann J, Bilo HJ, Cook HT, Cotlarciuc I, Davey Smith G, de Silva R, Deng G, Devuyst O, Dikkeschei LD, Dimkovic N, Dockrell M, Dominiczak A, Ebrahim S, Eggermann T, Floege J, Forouhi NG, Gansevoort RT, Han X, Homan van der Heide JJ, Hepkema BG, Hernandez-Fuentes M, Hypponen E, de Jong PE, Kleefstra N, Lagou V, Lapsley M, Luttrupp K, Marechal C, Nordfors L, Penninx BW, Perucha E, Pouta A, Roderick PJ, Ruokonen

A, Sanna S, Schalling M, Schlessinger D, Schlieper G, Seelen MA, Smit JH, Stenvinkel P, Sternberg MJ, Swaminathan R, Ubink-Veltmaat LJ, Wallace C, Waterworth D, Zerres K, Waeber G, Maxwell PH, McCarthy MI, Lightstone L. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*.478:103-109.

63. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics*. 2003;19:149-150.
64. Wolf SS, Patchev VK, Obendorf M. A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR. *Arch Biochem Biophys*. 2007;460:56-66.
65. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, Holm H, Sanna S, Kavousi M, Baumeister SE, Coin LJ, Deng G, Gieger C, Heard-Costa NL, Hottenga JJ, Kuhnel B, Kumar V, Lagou V, Liang L, Luan J, Vidal PM, Mateo Leach I, O'Reilly PF, Peden JF, Rahmioglu N, Soininen P, Speliotes EK, Yuan X, Thorleifsson G, Alizadeh BZ, Atwood LD, Borecki IB, Brown MJ, Charoen P, Cucca F, Das D, de Geus EJ, Dixon AL, Doring A, Ehret G, Eyjolfsson GI, Farrall M, Forouhi NG, Friedrich N, Goessling W, Gudbjartsson DF, Harris TB, Hartikainen AL, Heath S, Hirschfield GM, Hofman A, Homuth G, Hypponen E, Janssen HL, Johnson T, Kangas AJ, Kema IP, Kuhn JP, Lai S, Lathrop M, Lerch MM, Li Y, Liang TJ, Lin JP, Loos RJ, Martin NG, Moffatt MF, Montgomery GW, Munroe PB, Musunuru K, Nakamura Y, O'Donnell CJ, Olafsson I, Penninx BW, Pouta A, Prins BP, Prokopenko I, Puls R, Ruokonen A, Savolainen MJ, Schlessinger D, Schouten JN, Seedorf U, Sen-Chowdhry S, Siminovitsh KA, Smit JH, Spector TD, Tan W, Teslovich TM, Tukiainen T, Uitterlinden AG, Van der Klauw MM, Vasan RS, Wallace C, Wallaschofski H, Wichmann HE, Willemsen G, Wurtz P, Xu C, Yerges-Armstrong LM, Abecasis GR, Ahmadi KR, Boomsma DI, Caulfield M, Cookson WO, van Duijn CM, Froguel P, Matsuda K, McCarthy MI, Meisinger C, Mooser V, Pietilainen KH, Schumann G, Snieder H, Sternberg MJ, Stolk RP, Thomas HC, Thorsteinsdottir U, Uda M, Waeber G, Wareham NJ, Waterworth DM, Watkins H, Whitfield JB, Wittman JC, Wolffenbuttel BH, Fox CS, Ala-Korpela M, Stefansson K, Vollenweider P, Volzke H, Schadt EE, Scott J, Jarvelin MR, Elliott P, Kooner JS. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nat Genet*. 2012;43:1131-1138.
66. Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, Kooner JS, Mooser V. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. *Am J Hum Genet*. 2008;83:520-528.
67. Chasman DI, Pare G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan S, Malarstig A, Ordovas JM, Ripatti S, Parker AN, Miletich JP, Ridker PM. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. *PLoS Genet*. 2009;5:e1000730.
68. Soranzo N, Spector TD, Mangino M, Kuhnel B, Rendon A, Teumer A, Willenborg C, Wright B, Chen L, Li M, Salo P, Voight BF, Burns P, Laskowski RA, Xue Y, Menzel S, Altshuler D, Bradley JR, Bumpstead S, Burnett MS, Devaney J, Doring A, Elosua R, Epstein SE, Erber W, Falchi M, Garner SF, Ghorji MJ, Goodall AH, Gwilliam R, Hakonarson HH, Hall AS, Hammond N, Hengstenberg C, Illig T, Konig IR, Knouff CW, McPherson R, Melander O, Mooser V, Nauck M, Nieminen MS, O'Donnell CJ, Peltonen L, Potter SC, Prokisch H, Rader DJ, Rice CM, Roberts R, Salomaa V, Sambrook J, Schreiber S, Schunkert H, Schwartz SM, Serbanovic-Canic J, Sinisalo J, Siscovick DS, Stark K, Surakka I, Stephens J, Thompson JR, Volker U, Volzke H, Watkins NA, Wells GA, Wichmann HE, Van Heel DA, Tyler-Smith C, Thein SL, Kathiresan S,

Perola M, Reilly MP, Stewart AF, Erdmann J, Samani NJ, Meisinger C, Greinacher A, Deloukas P, Ouwehand WH, Gieger C. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. *Nat Genet.* 2009;41:1182-1190.

69. Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, Tofler G, Lin SJ, Kraja AT, Province MA, Yang Q, Becker DM, O'Donnell CJ, Becker LC. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. *Nat Genet.* 2010;42:608-613.
70. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P, Baumert J, Strachan DP, Fuchsberger C, Vitart V, Wilson JF, Pare G, Naitza S, Rudock ME, Surakka I, de Geus EJ, Alizadeh BZ, Guralnik J, Shuldiner A, Tanaka T, Zee RY, Schnabel RB, Nambi V, Kavousi M, Ripatti S, Nauck M, Smith NL, Smith AV, Sundvall J, Scheet P, Liu Y, Ruukonen A, Rose LM, Larson MG, Hoogeveen RC, Freimer NB, Teumer A, Tracy RP, Launer LJ, Buring JE, Yamamoto JF, Folsom AR, Sijbrands EJ, Pankow J, Elliott P, Keaney JF, Sun W, Sarin AP, Fontes JD, Badola S, Astor BC, Hofman A, Pouta A, Werdan K, Greiser KH, Kuss O, Meyer zu Schwabedissen HE, Thiery J, Jamshidi Y, Nolte IM, Soranzo N, Spector TD, Volzke H, Parker AN, Aspelund T, Bates D, Young L, Tsui K, Siscovick DS, Guo X, Rotter JI, Uda M, Schlessinger D, Rudan I, Hicks AA, Penninx BW, Thorand B, Gieger C, Coresh J, Willemssen G, Harris TB, Uitterlinden AG, Jarvelin MR, Rice K, Radke D, Salomaa V, Willems van Dijk K, Boerwinkle E, Vasani RS, Ferrucci L, Gibson QD, Bandinelli S, Snieder H, Boomsma DI, Xiao X, Campbell H, Hayward C, Pramstaller PP, van Duijn CM, Peltonen L, Psaty BM, Gudnason V, Ridker PM, Homuth G, Koenig W, Ballantyne CM, Witteman JC, Benjamin EJ, Perola M, Chasman DI. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation.* 123:731-738.
71. Marzi C, Albrecht E, Hysi PG, Lagou V, Waldenberger M, Tonjes A, Prokopenko I, Heim K, Blackburn H, Ried JS, Kleber ME, Mangino M, Thorand B, Peters A, Hammond CJ, Grallert H, Boehm BO, Kovacs P, Geistlinger L, Prokisch H, Winkelmann BR, Spector TD, Wichmann HE, Stumvoll M, Soranzo N, Marz W, Koenig W, Illig T, Gieger C. Genome-wide association study identifies two novel regions at 11p15.5-p13 and 1p31 with major impact on acute-phase serum amyloid A. *PLoS Genet.* 6:e1001213.
72. Zhang YY, Gottardo L, Mlynarski W, Frazier W, Nolan D, Duffy J, Marescotti MC, Gervino EV, Johnstone MT, Mantzoros CS, Avogaro A, Doria A. Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. *Atherosclerosis.* 2007;191:121-127.
73. Hirano Y, Hendil KB, Yashiroda H, Iemura S, Nagane R, Hioki Y, Natsume T, Tanaka K, Murata S. A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. *Nature.* 2005;437:1381-1385.
74. Hara T, Hirano M, Nozawa H, Nakada K, Hirano Y, Oyama K, Hada T, Takagi T, Kikkawa H. [A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy]. *Gan To Kagaku Ryoho.* 2005;32:829-831.
75. Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ, Jin R, Zhou X, Bradbury LA, Appleton LH, Davis JC, Diekmann L, Doan T, Dowling A, Duan R, Duncan EL, Farrar C, Hadler J, Harvey D, Karaderi T, Mogg R, Pomeroy E, Pryce K, Taylor J, Savage L, Deloukas P, Kumanduri V, Peltonen L, Ring SM, Whittaker P, Glazov E, Thomas GP, Maksymowych WP, Inman RD, Ward MM, Stone MA, Weisman MH, Wordsworth BP, Brown MA. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. *Nat Genet.* 2010;42:123-127.

76. Shur I, Zilberman M, Benayahu D, Einav S. Adhesion molecule expression by osteogenic cells cultured on various biodegradable scaffolds. *J Biomed Mater Res A*. 2005;75:870-876.
77. Surapureddi S, Viswakarma N, Yu S, Guo D, Rao MS, Reddy JK. PRIC320, a transcription coactivator, isolated from peroxisome proliferator-binding protein complex. *Biochem Biophys Res Commun*. 2006;343:535-543.
78. Zheng B, Ma YC, Ostrom RS, Lavoie C, Gill GN, Insel PA, Huang XY, Farquhar MG. RGS-PX1, a GAP for GalphaS and sorting nexin in vesicular trafficking. *Science*. 2001;294:1939-1942.
79. Friedmann E, Hauben E, Maylandt K, Schleegeer S, Vreugde S, Lichtenthaler SF, Kuhn PH, Stauffer D, Rovelli G, Martoglio B. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. *Nat Cell Biol*. 2006;8:843-848.
80. Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Luckerath K, Friedmann E, Novac N, Wels WS, Martoglio B, Hueber AO, Zornig M. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. *Cell Death Differ*. 2007;14:1678-1687.
81. Liu YH, Cheng CC, Ho CC, Chao WT, Pei RJ, Hsu YH, Ho LC, Shiu BH, Lai YS. Plectin deficiency on cytoskeletal disorganization and transformation of human liver cells in vitro. *Med Mol Morphol*. 2011;44:21-26.
82. Yang IV, Jiang W, Rutledge HR, Lackford B, Warg LA, De Arras L, Alper S, Schwartz DA, Pisetsky DS. Identification of novel innate immune genes by transcriptional profiling of macrophages stimulated with TLR ligands. *Mol Immunol*. 2011;48:1886-1895.
83. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Wittteman JC, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruukonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, Konig IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllenstein U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA, Jr., Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM,

Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 466:707-713.

84. Takegahara N, Kang S, Nojima S, Takamatsu H, Okuno T, Kikutani H, Toyofuku T, Kumanogoh A. Integral roles of a guanine nucleotide exchange factor, FARP2, in osteoclast podosome rearrangements. *FASEB J*. 2010;24:4782-4792.
85. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJ, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. *Nat Genet*. 2010;42:132-136.
86. Crowther-Swanepoel D, Corre T, Lloyd A, Gaidano G, Olver B, Bennett FL, Doughty C, Toniolo D, Caligaris-Cappio F, Ghia P, Rossi D, Rawstron AC, Catovsky D, Houlston RS. Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. *Blood*. 2010;116:5957-5960.
87. Su Z, Cox A, Shen Y, Stylianou IM, Paigen B. Farp2 and Stk25 are candidate genes for the HDL cholesterol locus on mouse chromosome 1. *Arterioscler Thromb Vasc Biol*. 2009;29:107-113.
88. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science*. 2007;316:1331-1336.
89. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Champion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F,

- Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet.* 2011;43:429-435.
90. Taylor KC, Lange LA, Zabaneh D, Lange E, Keating BJ, Tang W, Smith NL, Delaney JA, Kumari M, Hingorani A, North KE, Kivimaki M, Tracy RP, O'Donnell CJ, Folsom AR, Green D, Humphries SE, Reiner AP. A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARE) Consortium. *Hum Mol Genet.* 2011;20:3525-3534.
91. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, Soranzo N, Hayward C, Rudan I, Sabater-Lleal M, Bis JC, de Maat MP, Rumley A, Kong X, Yang Q, Williams FM, Vitart V, Campbell H, Malarstig A, Wiggins KL, Van Duijn CM, McArdle WL, Pankow JS, Johnson AD, Silveira A, McKnight B, Uitterlinden AG, Aleksic N, Meigs JB, Peters A, Koenig W, Cushman M, Kathiresan S, Rotter JJ, Bovill EG, Hofman A, Boerwinkle E, Tofler GH, Peden JF, Psaty BM, Leebek F, Folsom AR, Larson MG, Spector TD, Wright AF, Wilson JF, Hamsten A, Lumley T, Witteman JC, Tang W, O'Donnell CJ. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. *Circulation.* 2010;121:1382-1392.
92. Below JE, Gamazon ER, Morrison JV, Konkashbaev A, Pluzhnikov A, McKeigue PM, Parra EJ, Elbein SC, Hallman DM, Nicolae DL, Bell GI, Cruz M, Cox NJ, Hanis CL. Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. *Diabetologia.* 2011;54:2047-2055.
93. Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, Kotsch M, Schomig A. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. *Arterioscler Thromb Vasc Biol.* 1997;17:3399-3405.
94. Oikonomou KG, Zachou K, Dalekos GN. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. *Autoimmun Rev.* 2011;10:389-396.
95. Harazaki M, Kawai Y, Su L, Hamazaki Y, Nakahata T, Minato N, Hattori M. Specific recruitment of SPA-1 to the immunological synapse: involvement of actin-bundling protein actinin. *Immunol Lett.* 2004;92:221-226.
96. Izaguirre G, Aguirre L, Hu YP, Lee HY, Schlaepfer DD, Aneskievich BJ, Haimovich B. The cytoskeletal/non-muscle isoform of alpha-actinin is phosphorylated on its actin-binding domain by the focal adhesion kinase. *J Biol Chem.* 2001;276:28676-28685.
97. Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y, Kitamura N. Activation of the zymogen of hepatocyte growth factor activator by thrombin. *J Biol Chem.* 1993;268:22927-22932.
98. van Minkelen R, de Visser MC, Houwing-Duistermaat JJ, Vos HL, Bertina RM, Rosendaal FR. Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. *Arterioscler Thromb Vasc Biol.* 2007;27:1486-1491.
99. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, Thorleifsson G, Helgadottir H, Steinthorsdottir V, Stefansson H, Williams C, Hui J, Beilby J, Warrington NM, James A, Palmer LJ, Koppelman GH, Heinzmann A, Krueger M, Boezen HM, Wheatley A, Altmuller J, Shin HD, Uh ST, Cheong HS, Jonsdottir B, Gislason D, Park CS, Rasmussen LM, Porsbjerg C, Hansen JW, Backer V, Werge T, Janson C, Jonsson UB, Ng MC, Chan J, So WY, Ma R, Shah SH, Granger CB, Quyyumi AA, Levey AI, Vaccarino V, Reilly MP, Rader DJ, Williams MJ, van Rij AM, Jones GT, Trabetti E, Malerba G, Pignatti PF, Boner A, Pescolliderung L, Girelli D, Olivieri O, Martinelli N, Ludviksson BR, Ludviksdottir D, Eyjolfsson GI, Arnar D, Thorgeirsson G, Deichmann K, Thompson PJ, Wjst M, Hall IP, Postma DS, Gislason

T, Gulcher J, Kong A, Jonsdottir I, Thorsteinsdottir U, Stefansson K. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nat Genet.* 2009;41:342-347.

100. Savenije OE, Kerkhof M, Reijmerink NE, Brunekreef B, de Jongste JC, Smit HA, Wijga AH, Postma DS, Koppelman GH. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. *J Allergy Clin Immunol.* 2011;127:750-756 e751-755.
101. Winnepeninckx B, Debacker K, Ramsay J, Smeets D, Smits A, FitzPatrick DR, Kooy RF. CGG-repeat expansion in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1. *Am J Hum Genet.* 2007;80:221-231.
102. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, Spain SL, Broderick P, Domingo E, Farrington S, Prendergast JG, Pittman AM, Theodoratou E, Smith CG, Olver B, Walther A, Barnetson RA, Churchman M, Jaeger EE, Penegar S, Barclay E, Martin L, Gorman M, Mager R, Johnstone E, Midgley R, Niittymaki I, Tuupanen S, Colley J, Idziaszczyk S, Thomas HJ, Lucassen AM, Evans DG, Maher ER, Maughan T, Dimas A, Dermitzakis E, Cazier JB, Aaltonen LA, Pharoah P, Kerr DJ, Carvajal-Carmona LG, Campbell H, Dunlop MG, Tomlinson IP. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. *Nat Genet.* 2010;42:973-977.
103. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsater H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Roge B, Heron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat Genet.* 2007;39:25-27.
104. Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, Selicorni A, Zuffardi O. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. *Am J Hum Genet.* 2001;69:261-268.
105. Huett A, Leong JM, Podolsky DK, Xavier RJ. The cytoskeletal scaffold Shank3 is recruited to pathogen-induced actin rearrangements. *Exp Cell Res.* 2009;315:2001-2011.
106. Miljkovic I, Yerges LM, Li H, Gordon CL, Goodpaster BH, Kuller LH, Nestlerode CS, Bunker CH, Patrick AL, Wheeler VW, Zmuda JM. Association of the CPT1B gene with skeletal muscle fat infiltration in Afro-Caribbean men. *Obesity (Silver Spring).* 2009;17:1396-1401.
107. Germain M, Saut N, Greliche N, Dina C, Lambert JC, Perret C, Cohen W, Oudot-Mellakh T, Antoni G, Alessi MC, Zelenika D, Cambien F, Tiret L, Bertrand M, Dupuy AM, Letenneur L, Lathrop M, Emmerich J, Amouyel P, Tregouet DA, Morange PE. Genetics of venous thrombosis: insights from a new genome wide association study. *PLoS One.* 2011;6:e25581.